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Abstract 
This study investigated the immunomodulatory effect of an antithyroid drug, 
methimazole (MMI), on macrophages and lymphocytes of inbred mice. When the 
mice were treated with MMI in vivo, the expression of tumour necrosis factor (TNF) 
gene and the production of reactive nitrogen intermediates (RNI) and superoxide anion 
(02") were partially inhibited in peritoneal macrophages following in vitro stimulation 
with bacterial endotoxin. These effects may be attributed to a cellular accumulation 
of MMI in macrophages because MMI binds to their endogenous peroxidase. 
However, this possibility is ruled out by the demonstration that in vivo MMI treatment 
inhibited the mitogenic responses of splenic lymphocytes which do not contain 
peroxidase activity. The abilities of the splenocytes to produce lymphokines， 
including interleukin-2 (IL-2) and gamma interferon (IFNy) were impaired, thereby 
further hindering the macrophage function. In addition, co-incubation with 1-1000 pM 
MMI solutions did not alter the production of TNF, RNI and 0 / by macrophages and 
the mitogenic responses of splenic lymphocytes, indicating that the immunosuppressive 
effect of the MMI treatment was not caused by its cellular accumulation. 
In order to demonstrate that the immunomodulatory effects of MMI were 
mediated by its antithyroid activity, MMI-treat€d mice received subcutaneous 
injections of T4 for 6 consecutive days: Mice which received in vivo MMI treatment 
up to 6 weeks had a significant decrease of serum and cellular (macrophage and 
lymphocyte) thyroxine (T4) and macrophage triiodothyronine (T3)，with the exception 
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that serum and lymphocyte T3 remained at the control levels. The results showed that 
the suppressive effects of MMI on macrophages and lymphocytes correlated with the 
levels of serum and cellular T4, and both the serum thyroid hormone levels and 
cellular functions could be normalised by T4 replacement. These results indicate that 
MMI exerted its immunological effects through inhibiting thyroid hormone synthesis 
and circulating and cellular thyroid hormones, which subsequently hindered the 
immune response of macrophages and lymphocytes. 
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Chapter 1 General Introduction 
Introduction 
Thyroid hormones play an important role in cell differentiation and 
metabolism. They are synthesized by follicular cells in the thyroid gland. Up to 90 
% of the thyroidal output is 3,5,3',5'-tetraiodothyroinine (thyroxine, T4), while about 
10 % is 3,5,3'-triiodothyronine (T3) (Larsen, 1982). T4 is the dominant secreted and 
circulating form of thyroid hormone, whereas the major portion of T3 is derived 
extrathyroidally from circulating T4 (DeGroot & Niepomnisczcze，1975). When iodide 
availability is restricted, the intrathyroidal formation of T3 is favoured because it is 
about four to ten times more potent than T4, and thus more active honnone per 
molecule of iodide is generated (Oppenheimer, 1985). 
Thyroid hormone synthesis 
All forms of thyroid hormones are synthesized in the form of thyroglobulin, 
which is the major molecule in the colloid of the follicular lumen (van Herle ^ aL, 
1979). The thyroglobulin molecule contains an especially high proportion of tyrosine 
residues which are iodinated to form the thyroid hormones. Inorganic iodide from the 
extracellular fluid is concentrated by active transport into the follicular cells 
(Bastomsky aL, 1974), and rapidly oxidized by an enzyme, thyroid peroxidase 
(TPO), to form a reactive iodine free radical which is released into the follicular 
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lumen. Within the lumen, iodine combines with tyrosine residues of the thyroglobulin 
to form the hormones, triiodothyronine (T3) and tetraiodothyronine (T4). Very little 
rT3 is synthesized at this stage. The thyroid hormones are stored in the colloid until 
they are secreted into the circulation upon stimulation (DeGroot & Niepomnisczcze， 
1975), 
Thyroid hormone and thyroid diseases 
Hypothyroidism and hyperthyroidism are the two major thyroid disorders 
which may be further categorized into specific thyroid diseases. In general, all these 
diseases are caused by an abnormal synthesis of thyroid hormones. 
Hypothyroidism 
The clinical indications of hypothyroidism range from subclinical 
hypothyroidism to myxoedema coma. In subclinical hypothyroidism, most patients 
have normal levels of T4 and T3 but an elevated level of thyroid stimulating honnone 
(TSH). In mild hypothyroidism, the serum T4 level tends to fall before the serum T3 
level. This probably reflects a compensatory mechanism whereby smaller amounts of 
iodine are utilized to produce a metabolically more potent thyroid hormone (Evered, 
1975). In more severe case of hypothyroidism such as Hashimoto's thyroiditis, both 
serum T4 and T3 concentrations fall to the subnormal level. Note that serum T3 has 
little value in the confirmation of hypothyroidism because it is frequently normal, even 
when the patient is clinically hypothyroid (Hamburger, 1991). 
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Hyperthyroidism 
By definition, hyperthyroidism is an endocrinologic disorder characterized by 
elevated levels of thyroid hormones. Measurement of T3 is more important in the 
diagnosis of hyperthyroidism than hypothyroidism because the increase in T3 secretion 
in hyperthyroidism is proportionately greater than the increase in T4 secretion 
(Greenspan & Rapoport, 1991). Patients with Graves，disease may have an elevated 
serum T3 level but a normal T4 level, and both serum T4 and T3 levels are increased 
only in more severe c a s e s . : 
Graves' disease as an autoimmune disease 
Graves，disease is the commonest cause of thyrotoxicosis and it may occur at 
any age, more commonly in females than in males. The cause of the disease is not 
yet known. The present concept of the development of Graves' disease is that it is 
an autoimmune disease in which T lymphocytes infiltrate into the thyroid gland and 
then become sensitized to antigens, thus stimulating B lymphocytes to synthesize 
autoantibodies (Weetinan & McGregor, 1984; Burman & Baker，1985). One such 
autoantibody, thyroid stimulating immunoglobulin (TSI), is directed against the thyroid 
stimulating hormone (TSH) receptor and initiate all the biological activities of the 
natural tropic hormone (McGregor, 1990). Volpe (1987) has suggested that the 
generation of TSI is due to a defect in suppressor T cell function and thus allows the 
helper T cells to stimulate B lymphocytes to produce immunoglobulins directed 
against the thyroid gland. In addition, the serum interleukin-2 (IL-2) receptor 
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concentration and gamma-interferon (IFNy) production by helper T cells were also 
elevated in the case of hyperthyroidism. (Chow et al.，1990). 
Methimazole as an antithyroid drug 
Structure 
Thionamides coimnonly refer to a class of chemical compounds that have a 
thiocarbamide backbone incorporated into a six membered heterocyclic ring. Their 
antithyroid activity is attributed to the thiocarbamide group (S-C-N). The major 
thionamides include thiouracil, propylthiouracil (6-n-propyl-2-thiouracil, PTU), 
carbimazole and methimazole (l-metliyl-2-mercaptoimidazole, MMI). MMI and PTU 
have been available for many years and are still the most commonly used drugs for 
the treatment of hyperthyroidism in the United States and Europe. 
Action 
Once MMI gains entry into the body，it is concentrated in the thyroid gland by 
either an active, saturable, TSH-regulated system or passive diffusion into the thyroid 
cells at high concentrations (Pinchera et al., 1969), and exerts a wide spectrum of 
actions on thyroid honnone synthesis. These include: 
L MMI inhibits iodination of tyrosine residues on the thyroglobulin 
molecule by interacting with TPO. MMI suppresses initial TPO-
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mediated iodine oxidation and subsequent iodination of thyroglobulin 
( L e e r a l . , 1991). 
2. MMI inhibits the TPO-mediated coupling reaction and directly alters 
thyroglobulin structure by a mechanism which possibly impairs amino 
acid incorporation into the polypeptide backbone and attachment of 
necessary oligosaccharide chains (Monaco et al” 1980). 
3. MMI may also affect thyroid hormone production by influencing the 
growth of thyroid cell. Taniguchi (1989) and Leer (1991) have 
demonstrated that MMI inhibited the growth of the rat thyroid cell line, 
FRTL-5, following insulin-like growth factor stimulation. 
Use 
MMI is preferred under several conditions because of its longer half life and 
higher potency (Dorin, 1991). The first is the obvious case of the patient who refuses 
other forms of�treatment. The second reason is to cool down very severe 
hyperthyroidism in patients before definitive treatment with 131L The final reason to 
use antithyroid medications is to postpone another therapy until a more appropriate 
timQ. For instance, a juvenile patient with Graves，disease is usually treated with an 
antithyroid drug so as to avoid the harmful effects of 131I on growth and development. 
When MMI is given to a patient with Graves，disease, there is a delay in response 
since large amounts of T3 and T4 have already been stored in the thyroid gland. After 
several weeks of MMI treatment, the intrathyroidal hormone store is depleted and the 
output of thyroid hormones diminishes. The patient shows marked improvement 
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including diminished sweating, a drop in pulse rate and a fall in basal metabolic rate 
(McGregor et al” 1980). 
Immunomodulatory effect of MMI 
The effect of thionamides on the immune system was first described in 1967 
when Michie and colleagues observed a reduction in thymic size following thionamide 
therapy. This immunosuppressive characteristic of MMI is also asserted as a 
mechanism of this drug when it is used to treat autoimmune thyroid diseases 
(DeGroot, 1977; Hallengren er 1980; Bagnasco et al., 1990). Numerous studies 
have been conducted to examine the effects of MMI on the immune system. The 
evidences so far seem, however, to be controversial. 
In vitro effect 
MMI has been reported to decrease or suppress autoantibody secretion in 
patients with Graves' disease (McGregor et aL, 1980), 3H-thymidine incorporation into 
lymphocytes (Wall et al” 1974), mitogenic activation of lymphocyte immunoglobulin 
production (Weiss & Davies, 1981), antibody-dependent cell-mediated cytotoxicity 
(Pozzilli et al.’ 1982)，and hydrogen peroxide and oxygen free radical production from 
mononuclear cells (Balazs al, 1986). On the other hand, MMI has been shown to 
enhance concanavalin A (Con A)-induced activation of lymphocytes (Haliengren et 
1980; Okabe al., 1983; Sharma & Elias, 1987)，suppressor cell activity (Okabe 
et ai“ 1984)，B cell differentiation factor and IL-2 production (Weetman, 1986). 
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Some other studies suggested that MMI exerted no effect on cell-mediated cytotoxicity 
(Weetman et al” 1985), phytohemagglutinin (PHA)-induced T cell proliferation 
(Bagnasco et al., 1990) and interleukin-1 (IL-1) and IFNy production (Weetman, 
1986). 
In vivo effect 
MMI has been demonstrated to decrease mononuclear thyroidal infiltration, 
follicular destruction and splenic immune response (Davies et al” 1984). Rennie and 
colleagues (1983) also reported that MMI reduced the degree of experimental 
autoimmune thyroiditis and circulating autoantibodies in the rat. Clinically, patients 
undergoing thionamide therapy may experience a decline in thyroid autoantibodies 
(Fenzi et ¢//., 1979; Bech et al” 1980) and the levels of HLA-DR antigen, IFNy and 
IL-2 receptor (Tottennan et al” 1987). Mice treated with MMI have decreased 
tumoricidal activity, proliferative responses of lymphocytes to mitogens, activities of 
lysosomal enzyme and TNF production by macrophages (Liu et al., 1989; 1991). 
Immunomodulatory role of thyroid hormones 
Since MMI affects thyroid honnone synthesis, it is possible that its 
immunomodulatory effect is due to a direct action on the thyroid gland. It has long 
been known that thyroid hormones may influence the efficiency of the immune 
system. Hypothyroidism was found to reduce the production of antibodies in 
thyroidectomized rats (Fabris, 1973), total white blood cell counts and numbers of 
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lymphocytes (Wall et ai, 1981; Scoot & Glick，1987)，proportion of suppressor T 
cells in spleen (Pacini et a1., 1983) and blastogenic response of the lymphocytes 
(Chatterjee & Chandel, 1983). Patients with severe hypothyroidism have been 
reported to be more susceptible to infectious agents (Stanbury & DeGroot, 1964) 
which may be closely related to the decreased bactericidal capacity of neutrophils 
(Palmblad ^r ai, 1981) and diminished lysosomal enzyme activity in macrophages 
(Starling & Weese, 1985). All these results showed that the immune response was 
impaired in hypothyroidism. 
Macrophages and lymphocytes 
Macrophages and lymphocytes are two major immune cell types that are 
important for both cell-mediated and humoral immunity. There are two 
subpopulations of lymphocytes, namely T and B lymphocytes. When stimulated by 
an antigen, T lymphocytes form clones and produce various subclasses of effector T 
cells. These include cytotoxic T cells, helper T cells and suppressor T cells.. 
Cytotoxic T cells can directly destroy target cells by producing cytotoxic lymphokines. 
Helper T cells secrete inteiieukin-2 (IL-2) and stimulate help B cells to produce 
antibodies (Meidema & Melief, 1985)‘ Suppressor T cells inhibit B cells from 
producing antibodies. 
Macrophages plays an essential role in nonspecific phagocytosis and antigen 
presentation to T cells. T lymphocytes are thus activated to release lymphokines and, 
in turn, enhances the macrophage phagocytic effectiveness. In addition to their 
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classical functions, macrophages and lymphocytes have recently been found to produce 
a wide array of lymphokines which are important for cell interactions (Arai et al., 
1990) and production of other soluble effectors, such as TNF (Strieter et al” 1989b), 
reactive nitrogen intermediates (RNI) and reactive oxygen intermediates (ROI) (Mauel 
et al.’ 1991; Schreck & Baeuerle, 1991) which are important in the humoral function 
of macrophages and lymphocytes (Arai et al” 1990; Phillips et al” 1990) 
Objectives of study 
In view of the discrepancy in the immunoinodulatory effect of MMI treatment 
reported in the literature, this study investigated the action of MMI, both in vivo and 
in vitro, on the immune system of inbred mice. Macrophages and lymphocytes were 
collected from MMI-treated mice, and the production of TNF, RNI and ROI by 
macrophages was determined in Chapter 2 whereas the proliferative responses of 
lymphocytes and the content of crude lymphokines were shown in Chapter 3. The 
cytotoxicity and direct effects of MMI on macrophages and lymphocytes were, studies 
in Chapter 4, and finally serum and cellular thyroid honnones wei:e correlated with the 
duration of MMI treatment, as well as with the cell functions. This impairment in cell 
function can be recovered by thyroid hormone replacement which is shown in Chapter 
. . 5 . : . . : . ‘ . . . 
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Chapter 2 The Effect oi In Wvo Methimazole Treatment on the 
Functions of Macrophages 
Introduction 
Macrophages are derived from blood monocytes which ai'ise from hemopoietic 
stem cells in the bone marrow. They play a central role in cell-mediated immunity, 
both in the initiation of response as antigen-presenting cells and in the effector phase 
as inflammatory, tumoricidal and microbicidal cells. These functions are activated with 
signals derived from lymphocytes such as interleukin-2 (IL-2) and gamma-interferon 
(IFNy). IFNy is a potent regulator of major histocompatibility complex (MHC) which 
is essential in the immune response to foreign antigens. It can up-regulate the 
expression of both MHC class I and class II antigens in macrophages, class I being 
required for recognition of foreign antigens by cytotoxic T lymphocytes and class II 
for foreign antigen by T-helper cells (Meager, 1990). However, this activation step in 
itself is insufficient to trigger macrophage cytotoxic function. It only primes 
macrophages to respond to secondary stimulants such as bacterial lipopolysaccharide 
(LPS)‘ The synergy of IFNy and LPS enhances the release of tumor necrosis factor 
(TNF), reactive oxygen intermediates (ROI, such as superoxide anion and hydrogen 
peroxide) and reactive nitrogen intermediates (RNI) by macrophages. These secretions 
are considered to be actively involved in the macrophage microbicidal and tumoricidal 
activities (Phillips et al” 1990). 
. . . : . 1 0 
Tumour necrosis factor 
Cai-swell and his colleagues (1975) reported the presence of tumor necrosis 
factor (TNF) in the serum of mice infected with Bacillus Calmette-Guerin and 
subsequently challenged with bacterial endotoxin. TNF is a polypeptide which can 
induce haemoiThagic necrosis of some solid tumours in mice (Carswell et al., 1975) 
as well as cytostatic or cytotoxic effect to a panel of tumor cell lines in vitro (Mattews 
& Neale, 1978; Sugerman et al” 1987; Beulter & Cerami，1988; Balk will, 1989). It 
is mainly produced by activated macrophages in response to gamma-interferon (IFNy), 
lipopolysacchai-ide (LPS) or 12-o-tetradecan6yl-phorbol-13-acetate (TPA) stimulation 
(Aggarwal et al., 1985; Black et 1987; Keller ^ 1989; Stuehr & Nathan， 
1989), a process controlled by protein kinases (Schutze et al., 1990). Activation of 
protein kinase C (PKC) stimulates TNF transcription and the cleavage of 17 kd TNF 
molecules from their 26 kd membrane-integrated precursor molecules (Nishizuke, 
1986; Kronke 权 a/., 1990). This positive regulatory pathway is counteracted by 
protein kinase A (PKA) as well as prostaglandin E2 (PGE2) at the transcriptional level 
(Kunkei a/., 1986； 1988; Scales et 1989; Kioiikt et ai., 1990). It was 
recognized that TNF itself acted as a membrane-embedded trimer which formed ion-
permeable channels on the target cell, and thus exerted its cytotoxic effect (Kagan et 
fl/.，1992). Two receptors for TNF were also recently isolated (Naume et al., 1991; 
Tartaglia & Goeddel，1992). Moreover, microinjection of TNF induced DNA 
fragmentation in the target cells (Smith et al” 1990). Therefore, TNF is considered 
to be an important effector molecule in the non-specific tumoricidal activity of 
activated macrophages. 
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Reactive nitrogen intermediates (RNI) 
In macrophages, RNI represent an important effector of tumoricidal and 
microbicidal activities which are contributed by the metabolism of L-ai*ginine through 
a pathway producing N02/N03' and citrulline (Hibbs et al., 1987a,b; Stuehr et aL, 
1989; Keller & Keist，1989). The cytotoxicity of RNI is due to the production of a 
reactive radical nitric oxide (NO ) during metabolism of L-arginine (Hibbs etaL, 1988; 
Stuehr & Nathan, 1989; Nathan & Hibbs，1991), while NO^/ N0 3 ' is released only as 
a stable metabolite without any cytostatic activity (Stuehr et <3/., 1989; Takema et al,, 
1991). NO is synthesized by cytosolic NO. synthase in activated macrophage 
following exposure to cytokines and endotoxin (Lyons et 1992; Xie et al” 1992). 
NO inhibits mitochondrial respn-ation (complex I and complex II of 
mitochondrial electron transport chain), the citric acid cycle enzyme aconitase and 
enzymes with iron-sulphur prosthetic groups in tumour cells (Hibbs er a I., 1987b; 
Drapier & Hibbs，1988), However excessive production of NO' not only destroys to 
tumour cells but also macrophages themselves, although the latter are reported to be 
less sensitive and susceptible to the attack of RNI (Takema al” 1991). Recently, 
NO has been identified as a multi-functional mediator which serves as a 
neurotransmitter (Snyder & Bredt, 1991)，an immune defence molecule (Mauel et al., 
1991) and a mediator in inflammatory and autoimmune-mediated tissue destruction 
(Kolb & Kolb-Bachofen, 1992). 
Reactive oxygen intermediates (ROI) 
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In response to appropriate stimuli, macrophages undergo an enhanced 
respiratory burst and oxygen uptake which is insensitive to inhibitors of mitochondrial 
respiration，suggesting that oxygen consumption is not used for energy production 
(Babior, 1978). It has been reported that at least part of the oxygen is converted to 
superoxide anion (02"), hydrogen peroxide (H202) and hydroxyl radical (OH) by 
NADPH oxidase, a membrane-bound enzyme on macrophages (Sasada & Johnston, 
1980; Schreck & Baeuerle，1991). ROI has been identified as agents that are 
important in the killing of neoplastic cells (Nathan et al., 1980) and intracellular 
microbes (Sasada & Johnston, 1980; Murray & Cohn，1979; Murray et al., 1979). 
The cytotoxicity of ROI is mediated by the peroxidation of unsaturated fatty acids in 
the target cells and thus affecting the integrity of the cell membrane (Hocking & 
Golde, 1979). Macrophages are protected from the cytolytic effect of ROI by 
converting the 02" to water via the production of H202，in the presence of superoxide 
dismutase (SOD) and catalase (Fridovich，1986). 
It has been demonstrated that rats and mice treated with methimazole in vivo 
had an impaired defense ability against tumour cells (Liu et al., 1989, 1991). This 
study tried to investigate the production of effective antitumour molecules including 
TNFj superoxide anion and RNI in macrophages collected from MMI-treated mice. 
The expression of TNF gene was studied using Northern blot analysis. 
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Materials and Methods 
MMI treatment 
One hundred male C57BL/6 mice, aged 8 - 10 weeks, were provided with 
0.1% methimazole (MMI, Sigma M8506, USA) in drinking water ad libitum for 6 
weeks. One hundred age-matched mice received tap water and were used as controls. 
The animals were housed under normal laboratory conditions (21 土 2�C，12/12 -
light/dark cycle) and maintained on standard rodent chow. 
Culture media 
DuIbecco’s modified Eagle's medium without phenol red (DMEM, D 2902)， 
Dulbecco，s phosphate buffered saline (PBS, D 5652)，Hank's balanced salts solution 
(HBSS, H 2387) and RPMI-1640 (R 6504) were purchased from Sigma Co (St. Louis, 
USA). Generally, medium powder was dissolved in 800 ml fresh double-distilled 
water. They were stirred gently for 3 - 4 h, and sodium bicarbonate was then added 
(2g, 3.79g and 0.35g for RPMI，DMEM and HBSS respectively). 0.1 g MgCl2«6 H 2 0 
(BDH, 10149, England) and 0.133 g CaCl2.2 H 2 0 (BDH，10070, England) were 
added into PBS. After the mixture had completely dissolved, the pH of the solution 
was adjusted to 7.2 and the final volume was made up to 1 L with fresh double-
distilled water. The medium was sterilized by passing through a sterile 0.22 pm 
millipore filter and stored in a sterile container at 4°G. RPMI and DMEM were 
supplemented with 10 % fetal bovine serum (Gibco, 200-61400AJ, USA), 
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streptomycin sulphate (100 pg/ml, Sigma, S9137, USA) and penicillin G (100 IU/ml, 
Sigma, P7794, USA). 
Peritoneal macrophage isolation and culture 
The animals were killed by cervical dislocation and thioglycollate (DIFCO, 
0236-01-05, USA)-elicited peritoneal exudate cells were collected from control and 
MMI-treated mice by aseptic peritoneal lavage with ice-cold HBSS (Liu et ciL’ 1989). 
The cells were washed, counted and suspended in supplemented RPMI at 2 x 106 
cells/ml. The number of viable cells was more than 95% as determined by the trypan 
blue exdlusion method (Phillips aL, 1990). Cell suspensions (2x 106 cells/ml) were 
allowed to settle in 24-well flat bottom culture plates at 37°C in a humidified 
atmosphere of 5% C02 for 3 h. Nonadherent cells were removed by vigorous washing 
with warm phosphate buffered saline (PBS) and the adherent macrophages were used 
for bioassays. 
Tumour necrosis factor production and bioassay 
Production of TNF in vivo 
Fifty mice primed with zymosan A (1 mg/mouse) for 5 days were challenged 
intravenously with lipopolysaccharide (LPS, Sigma L4391, USA) (25 pg/mouse) to 
produce TNF. Serum and peritoneal macrophages were collected at different time 
intervals (0，45 and 90 min), thereafter for TNF bioassay and Northern blot analysis 
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of TNF gene expression in peritoneal macrophages respectively. 
Production of TNF in vitro 
Adherent macrophages (2xl06 cells/well) were stimulated with LPS (1 pg/ml) 
for 0，1, 2 and 4 h and the cell-free culture medium was collected for TNF bioassay. 
For the study of TNF gene expression, cells (4x107 cells/dish) were cultured in a 10-
cm culture dish (Falcon 1029, USA), stimulated with the same concentration of LPS 
for 0，1，2 and 4 h； and the adhei-ent cells were lysed for Northern blot analysis of 
TNF t ranscr ip ts , , : 
TNF bioassay 
The TNF bioactivity in the cell-free culture medium was determined using the 
murine L929 fibroblast bioassay (Stiieter et al.’ 1989b; Liu et aL, 1991). L929 cells 
(Ix 104 cells/0.1 ml) were cultured in 96-well micro titer plates (Nunclon, Delta, USA) 
for 24 h at 3TG. The growth of the cells was mxested by incubating the cells in 
supplemented RPMI containing 2pg/ml actinomycin D (Sigma, A1410, St. Louis, 
USA) for 2 h, rinsed witli warm PBS containing Ca"^ and Mg"^ and further cultured 
with a serial dilution of TNF-containing culture medium for an additional 24 h. Viable 
adherent L929 cells were stained with crystal violet (0.5% in methanol/water, 1:4 v/v) 
for 5 min, and the dye taken up by the cells was extracted with acidic alcohol (1 % 
acetic acid in 50 % alcohol). The absorbance of each well was read at 595 nm with 
a microplate ELIZA reader (3550 Bio-Rad microplate reader, U.S.A.). The TNF 
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bioactivity was defined as the percent inhibition of L929 cell growth. 
O.D.medium - O .D . s a n i p , e 
% inhibition = X 100% 
nie<iiuni. 
O.D.medium = O.D. of L929 cells cultured in plain medium only. 
O.D.sample O.D. of L929 cells cultured in TNF-containing medium obtained from 
LPS-stimulated macrophages. 
Production of tumour necrosis factor mRNA 
Preparation of LB agar 
10 g bacto-tryptone (DIFCO，0118-02-7，USA), 5 g bacto-yeast extract 
(DIFCO, 0121-01-6) and 10 g NaCl (DBH) were first dissolved in 800 ml double 
distilled water and the pH was adjusted to 7.4. 15 g agar (DIFCO, 0001-01, USA) 
was then added and the final volume was adjusted to 1 L. The solution was 
autoclaved (121°C, 15 lb/in2), cooled down to 50°C, poured into petri dishes (10 cm 
diameter) aseptically, and allowed to set at room temperature for 2 h. The plates were 
stored at 4°C before use. 
Preparation of LB medium 
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10 g bacto-tryptone, 5 g bacto-yeast extract, and 10 g NaCl were dissolved in 
800 ml double distilled water. The pH was adjusted to 7.4 and the volume made up 
to 1 L. The solution was autoclaved, cooled down at room temperature and then 
stored at 4°C. 
Preparation of competent cells 
A single colony of Escherichia coli strain HB 101 was grown in sterile culture 
tube with 5 ml LB medium with constant shaking (100-200 rpm) at 37°C overnight. 
1 ml of the" overnight bacterial culture was inoculated into 99 ml fresh LB medium 
and the cells were further grown at 37�C until the absorbance of the mixture at 550 
nm was in the range of 0,3-0.4 (that is the logarithmic phase of growth for the 
bacterial culture). The culture was spun (1800 rpm) at 4°C for 10 min. The 
supernatant was discarded and the pellet was resuspended in 50 ml ice-cold solutions 
of 50 mM CaCl2-10 mM Tris.Cl (pH 8.0). The suspension was chilled on ice for 15 
min to enhance the bacteria to admit foreign DNA. The solution was centrifuged at 
2000 rpm and the competent cells were resuspended in 6.67 ml ice cold CaCl2-Tris 
• buffer. : . . 
Transformation of plasmid containing TNF and actin inserts 
10 pi of plasmid containing 0.2 ng TNF (Caput s al” 1985) or Actin (provided 
by Dr. C.C. Wong of GUHK) in Tris-EDTA buffer (pH 7.2) was mixed with 240 pi 
competent cells in a sterile microcentrifuge tube and chilled on ice. The plasmid was 
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transformed into competent cells by heat shock at 42°C for 2 min and cooled down 
on ice after incubation. 0.75 ml LB medium was added to the transformed cells and 
incubated at 3 7 � C for 1 h to allow the bacteria to recover and to begin to express 
antibiotic resistance. 
Growth of transformed bacteria 
The transformed HB 101 cells carrying the plasmid of TNF or actin DNA 
insert were able to grow on LB agar with 50 pg ampicillin (Sigma, A 9518, St. Louis, 
USA) because the DNA (TNF and actin) constructs contained ampicillin resistant 
gene. 4-6 colonies were randomly selected and cultured overnight in LB medium at 
37°C with shaking at 100 - 200 rpm. The culture was centrifuged at 2000 rpm at 4°C 
for 10 min and the pellet was resuspended in 2.25 ml glucose buffer (25 mM Tris, pH 
8.0, 50 mM glucose，and 10 mM EDTA). The cells were lysed with a fresh lysozyme 
solution (8 mg/ml in glucose buffer) and the DNA was released by incubating with 
6 ml 0.8 % NaOH - 1 % SDS at 4°C for 5 min. 
Isolation of total DNA from the bacteria 
DNA was precipitated in a solution of ice-cold 4M potassium acetate and spun 
(12000 rpm) at 4 °C for 10 min. The supernatant was transferred into another Corex 
centrifuge tube. 7.5 ml isopropanol was added into the supernatant and mixed by 
vortexing. The tube was placed in a - 2 0 � C freezer for 30 min. The tube was then 
spun (12000 rpm), at 4 °C for 15 min. The supernatant was discarded and the pellet 
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containing plasmid DNA was resuspended in 800 pi Tris-EDTA buffer (TE buffer, 10 
mM Tris.Cl，1 mM EDTA，pH 7.5) in a 1.5 ml microcentrifuge tube. Bacterial RNA 
was removed by incubating with 20 pg RNAase at room temperature for 15 min. The 
DNA in the solution was then extracted with 1 volume of phenol (equilibrated by 0.1 
% dehydroxyquinoline-1 M Tris at pH 8.0)，2 volumes of phenol-chlorofonn-isoamyl-
alcohol mixture (25:24:1 by volume) and 0.5 volume of chloroform-isoamyl-alcohol 
(24:1 by volume) successively to remove contaminated protein. The aqueous phase 
obtained after each extraction was transferred to a 2 ml microcentrifuge tube. 1/10 
volume of 3 M sodium acetate and 2.5 volumes of ice - cold ethanol were added. The 
plasmid DNA in the solution was then precipitated at » 70 °C for 1 h. After 
precipitation, the tubes were spun (12000 rpm) at 4 °G for 10 min and the solution 
was discarded. The pellet was rinsed with 1 ml 70 % alcohol, spun (12000 rpm) at 
4°C for 3 min and the DNA pellet was lyophilized for 10 min. The plasmid was 
resuspended in 10 pi TE buffer (pH 7.5). 
Extraction of TNF and actin DNA 
The TNF and actin DNA were separated from the plasmids by co-incubation 
with Pst I (New England Biolabs) and BamH I (New England Biolabs) and subjected 
to TAE agarose gel electrophoresis. Concentrated (40x) TAE stock solution consists 
of 193.6 g Tris base, 108.9 g sodium acetate.3 H20, and 12.5 g EDTA-Na2.2 H 2 0 in 
1 L double distilled H20, pH 7.0. 9 volumes of double distilled water and 1 volume 
of loading buffer (5 ml glycerol, 250 pi 40X TAE, 1 ml saturated bromophenol blue, 
mixed with 2.75 ml double distilled water to make a 10 ml stock) were mixed with 
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the extracted DNA and the mixture was incubated at 6 5 � C for 2 min. It was loaded 
onto a TAE agarose gel (0.5 g agarose and 5 pi ethidium bromide dissolved in 50 ml 
IX TAE solution) and IX TAE was used as running buffer. BstE II digest of lambda 
phage DNA was used as the marker DNA. 
Purification of TNF and actin DNA by Geneclean®II kit 
After electrophoresis, the gel containing DNA of correct size was cut and 
subjected to DNA elution using Geneclean®II kit (Bio 101 Inc., USA). The cut gel 
was placed in a 2-ml microcentrifuge tube and solubilized with 3 volumes of Nal (5.3 
M so that the final concentration of Nal was above 4 M). The tube was incubated at 
50 °C for 2 min to release DNA from the gel. ； DNA was allowed to bind onto the 
silica matrix of the glassmilk (provided in the Genedean®II kit, generally 5 pi for 5 
pg DNA, then 1 pi for additional 0.5 pg DNA). The pellet was washed three times 
with 200 - 700 pi ice cold NEW WASH®, and resuspended in Tris-EDTA buffer 
(same volume as that of glassmilk added). The mixture was incubated at 50 °C for 
3 min, spun at 12000 ipm for 30 §ec and the.supernatant was collected. The purified 
DNA was stored at - 20 °C before it was used for radiolabelled probe preparation. 
Total RNA extraction from macrophages 
: � � . c ‘ -i" ” ：“ .v': “ ./: .,：?、".，，• ,:. . n ； »‘ •"‘.…“• \ * “‘ “.” ‘ \ 
Total RNA was extracted according to the method of Karlinskey et al. (1989). 
Briefly, LPS-stimulated peritoneal macrophages (4 X 108 cells/10 ml/culture dish) 
were lysed using 3 ml 5 M guanidlnium thiocyanate (Merck, 820613，USA) and seven 
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volumes (21 ml) of 4 M lithium chloride (Merck, 5679, USA) was added to protect 
the RNA from RNAase. The lysate was incubated at 4 °C overnight and then spun 
(12000 rpm) at 4 °C for 1 h. The pellet was resuspended in 5 ml of 3 M lithium 
chloride and spun (12000 rpm) at 4 °C for 20 min. The pellet containing RNA was 
,solubilized in TE buffer containing 0.1 % SDS (pH 7.5), and purified by a series of 
phenol and chloroform extractions. The total RNA was resuspended in 10 pi TE 
buffer (pH 7.5) and its quantity was measured using a spectrophotometer at 260 nm. 
Separation of total RNA by electrophoresis 
RNA samples were then separated by electrophoresis in 1 % agarose-6 % 
formaldehyde gel. The gel consist of 0.5 g agarose in 36.08 ml autoclaved DEP H20 
(0.1 % diethylpyrocai'bonate solution), 5 ml 10X MOPS/EDTA (41.8 g 
moipholinopropane-sulfonic acid, 6.8 g sodium acetate, and 3.8 g tetrasodium EDTA 
salt dissolved in 1 L double distilled water, pH 7.0), 8.93 ml formaldehyde and 5 pi 
ethidium bromide. The running buffer was 250 ml IX MOPS/EDTA. The loading 
buffer was a mixture of 150 pi 10-fold dye (50 % glycerol + 1 inM EDTA, pH 7.4 
+ 0.4 % bromophenol blue), 150 pi 10-fold MOPS/EDTA, 255 pi 37 % formaldehyde 
and 750 pi formamide% RNA samples (20 pg) were mixed with 6.67 volumes of 
loading buffer incubated at 65 °C for 2 min and applied into the wells of formaldehyde 
gel. The RNAs were separated at 12 V overnight. 
Northern blot analysis 
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The separated RNA samples were transferred onto a Zeta Probe membrane 
/ 
(Bio Rad, USA). The blot was washed in 50 ml 2X BSC for 30 min and the RNA 
was crosslinked twice at 0.12 J/cm2 by a ultraviolet crosslinker (Spectrolinker XL 
1500 UV Crosslinker, Spectronics Corporation，USA). The blot was then ready for 
hybridization. 
Synthesis of TNF and actin probe� 
The TNF and actin probes were labelled with 32P-dCTP by random priming 
method. Briefly, 100 ng TNF DNA was mixed with 5 pi double-distilled water and 
0.125 U/1.25 pi hexamer (Pharmarcia 27-2166-01 random primers, USA) in a sterile 
microcentrifuge tube. The double-stranded DNA was separated by boiling for 2 min 
and then cooled down on ice immediately. 1 pi bovine serum albumin (10 mg/ml), 
5 pi 32P-dCTP (Amersham, USA), 0.75 pi Klenow fragment (5000 U/ml, Pharmacia 
27-0928-02, US A) and 10 pi reaction buffer (mixture of 0.5 M Hepes at pH 6.6，12.5 
mM MgCI2, 0.025 M B - mercaptoethanol? 0.125 M Tris pH 8.0, 50 pM dATP and 50 
pM dGTP, 50 pM dTTP) were added, bringing the total volume to 25 pi. The 
reaction was then allowed to proceed at 37 °C for 3 h. Before the reaction was 
completed, the reaction mixture was loaded onto a Sephadex G50 column with 150 
pi 10+1 TE - 0.1 % SDS (mixture of 5 ml of 2 M Iris at pH 7.5, 0.4 ml of 0.25 M 
EDTA，1 ml of 10 % SDS and 93.6 ml of double distilled water). The column was 
centrifuged at 300 lpm for 10 sec and the 32P-labelled TNF or actin was collected in 
an microcentrifuge tube. The radioactivity of the labelled probe was then measured 
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by a Beckman B-counter. The amount of the labelled probe used was about 1 million 
cpm per sample. 
Prehybridization 
The blot was prehybridized in 5 ml prehybridization solution, FSSSE (7 g SDS 
in 100 ml mixture containing 50 ml of 100 % formamide, 25 ml of 1 M NaHP04 at 
pH 7.2, 5 ml of % M NaCl, 0.5 ml of 0.5 M EDTA at pH 8.0 and 19.5 ml double-
distilled water) in a bottle which was under constant rotation at 42°C for 16 h. 
Hybridization with TNF and actin probe 
The pre-hybridization buffer in the bottle was replaced with 5 ml fresh FSSSE 
containing a 32P-dCTP labelled TNF or Actin DNA probe. The blot was hybridized 
under constant rolling at 42°C overnight. After hybridization, the blot was washed 
briefly in 0.1 % SDS - 2X SSC solution 3 times at room temperature and then in 0.1 
% SDS - 2 X SSC solution at a shaking speed of 200 lpm at room temperature for 15 
min. The blot was then shaken twice in 0.1 % SDS - 0.1 X SSC solution at 3 7 � C for 
15 min. The washed blot was wrapped in saran wrap and then exposed to a Kodak 
XAR - 5 film at - 70�C for 1 day. The film was developed and the autoradiographic 
signals were scanned with a densitometer (GS 3000, Hoefer, USA) to compare the 
band intensities. The relative intensity of TNF hybridization signal was normalised 
with equal amount of actin. 
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Measurement of reactive nitrogen intermediates (RNI) production 
In order to study the production of RNI by activated macrophages from control 
and MMI-treated mice, the level of N02", a stable metabolite of NO，in culture 
medium was measured. Adherent macrophages were cultured in the presence of either 
LPS (lpg/ml) alone or LPS together with diluted (1:1，v/v) crude lymphokines to 
stimulate the production of reactive nitrogen intermediates (RNI) (Keller & Keist， 
1989). Crude lymphokines were produced according to the method described in 
chapter 3 (Liu et al., 1989)； After incubation for 20h， 100 pi of cell-free culture 
medium was removed from each culture well and allowed to react with 50 pi of 
Griess reagent (1 % sulfanilamide and 0.1 % naphthylene diamine dihydrochloride in 
2.5 % H3PO4) for 10 min (Hibbs ^ ^//., 1987a), Plain DMEM solution was used as 
a negative control, which was assayed in parallel with the experimental samples. The 
N02" released was determined by an Eliza reader at 550nm, and calculated from a 
standard curve constructed with known concentrations of the N02" standard. The 
concentration of N O / was expressed as pM/million cells. 
Measurement of superoxide anion (02') 
Adherent macrophages were incubated in phosphate buffered saline (PBS) 
containing Ca"^ (0.133 g/L) and Mg^ (0.1 g/L), glucose (1 g/L), 1 pM phorbol 
12-myristate 13-acetate 4-O-methylester (TPA, Sigma P8139, USA) and 80 pM 
cytochrome C (Sigma, C2506, Type III, USA) at 3 7 � C for I h and the 02* released 
into the culture medium was detected using a microplate ELIZA autoreader at 550nm 
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(Pick & Mizel, 1981). The concentration of was calculated according to the 
following formula and was expressed as pM/million cells. 
absorbance550iuil x 100 
pM 02- = ^ 
6.3 
Analysis of Data. 
Results are expressed as means 土 standard deviation. Student's paired t test 
was used to compare the difference between control and experimental groups. The 
level of significance was taken at *p < 0.05, < 0.01 and 術 p < 0.001. 
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Results 
In vivo production of TNF 
The TNF bioactivity In the sera of C57BL/6 mice at various times after LPS 
stimulation was studied by using L929 fibroblasts which are especially susceptible to 
TNF, and was expressed as percent inhibition of L929 cell growth. Figure 2.1 shows 
that serum TNF level increased only upon stimulation with LPS and reached a peak 
at 45 min, and declined thereafter. The serum TNF level of MMI-ti*eated mice were 
generally lower than those of their respective controls. A significant difference (p < 
0.001) was found after 90 min of LPS treatment. Figures 2.2 & 2.3 show the 
Northern blot analysis of TNF transcripts in control macrophages (CM) and 
macrophages from MMI-treated mice (MM) following LPS administration. The level 
of TNF niRNA reached a maximum at 1 h after LPS injection in both groups and 
returned to the basal level in the next 2 h. The transcription of the TNF gene in MM 
following 1 h LPS administration was about 2/3 of the control value (Figure 2.3). 
Production of TNF in macrophage cultures 
The kinetics of TNF production in macrophage cultures were different from 
those in serum. The macrophages produced TNF progressively in the first four hours 
of in vitro LPS treatment in both CM and MM (Figure 2.4)，and MM showed 
significant decreases (p < 0.01 at 1 h and p < 0.001 at 2 and 4 h after LPS 
stimulation) in comparison to their respective controls. The production of TNF in vitro 
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was different from that of in vivo LPS challenge which reached the peak level at 45 
min and declined thereafter. 
Similai" results were found in the in vitro production of TNF mRNA, as 
determined by Northern blot analysis (Figures 2.5 and 2.6). TNF transcripts in CM 
and MM increased steadily and reached a maximal level at 2 h. CM produced a 
higher level of TNF mRNA upon stimulation after 1 h of LPS treatment, when 
compared with MM. In the absence of LPS, no TNF mRNA was detected, suggesting 
that the expression of TNF gene was due to LPS stimulation. 
Production of reactive nitrogen intermediates (RNI) 
Reactive nitrogen intermediates (RNI) are important for the tumoricidal activity 
of macrophages (Hibbs et al” 1988). The level of RNI was determined by the amount 
of nitrite (N02") which is a stable metabolite of RNI (Stuehr et al., 1989). In this 
experiment, macrophages were stimulated with LPS alone or LPS combined with 
crude lymphokines (Figure. 2.7). CM showed a stronger response to LPS and 
produced a significantly larger (p < 0.001) amount of N02", as compared to MM. LPS 
and crude lymphokines had a synergistic effect on N02" production in both CM and 
MM, but CM still produced significantly more (p < 0.01) N02" in comparison to MM. 
02" production 
Superoxide anion released from macrophages reacts simultaneously with 
28 
femcytochrome C and changes the absorbance at 550 nm. MM produced a lesser 
amount (p < 0.001) of 0 2 ' after administration with TPA for 1 h (Figure 2.8). 
Similarly； a decrease in 02" was produced by MM when stimulated by LPS (lpg/ml). 
This experiment also shows that TPA seems to be a more appropriate stimulant than 
LPS for in vitro production of superoxide anion by peritoneal macrophages. However, 
even stimulated with LPS, CM also produced a significantly higher level (p < 0.001) 
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Figure 2.1 Production of serum tumour necrosis factor (= inhibition of L929 cell 
growth) by control (CTL) and methimazole-treated (MMI) mice after 
intravenous injection of lipopolysaccharide (LPS, 25 pg/mouse). The 
results are expressed as means 土 standard deviation (n=12). ***p < 
0.001. 
30 
Figure 2.2 (upper) Northern blot analysis of tumour necrosis factor and actin 
transcripts in peritoneal macrophages isolated from control 
(CM) and methimazole-treated (MM) mice after intravenous 
lipopolysaccharide (LPS, 25 pg/mouse) challenge. 
Figure 2.3 (lower) Production of tumour necrosis factor transcripts by peritoneal 
macrophages from control (CM) and methimazole-treated (MM) 
mice in response to intravenous lipopolysacchai'ide (LPS) 
treatment The hybridization signals were normalized to an 
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Figure 2.4 In vitro production of tumour necrosis factor protein released by 
peritoneal macrophages isolated from control (CM) and methimazole-
treated (MM) mice. The cells were then stimulated in vitro with 
lipopolysaccharide (LPS, 1 pg/ml) for 1，2 and 4 h. The results are 
expressed as means 土 standard deviation (n=6). **p < 0.01，***p < 
0.001. 
33 
Figure 2.5 (upper) Northern blot analysis of tumour necrosis factor (TNF) and 
actin transcripts in peritoneal macrophages isolated from control 
(CM) and methimazole-treated (MM) mice. The cells were 
challenged with lipopolysaccharide (LPS, 1 pg/ml) in vitro for 
1, 2 and 4 h. 
Figure 2.6 (lower) Production of tumour necrosis factor (TNF) transcripts by 
• . • . . . . . . . •‘ . - • t - - . . . . . . • • , ‘ 
peritoneal macrophages Isolated, from control (CM) and 
methimazole-treated (MM) mice after challenge with 
lipopolysaccharide (1 pg/ml) in vitro for 1，2 and 4 h. The 
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Figure 2.7 Production of reactive nitrogen intermediates (RNI), as measured by the 
amount of nitrite (pM/million cells), by peritoneal macrophages isolated 
from both control (CM) and methimazole-treated (MM) mice. The cells 
were stimulated in vitro with lipopolysaccharide (LPS, 1 pg/ml), crude 
lymphokines (CLK) and a combination of LPS + CLK. The results are 
expressed as means ± standard deviation (n=12). **p < 0 . 0 1 ， < 
0.001. 
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Figure 2.8 Production of superoxide anion (pM/million cells) by peritoneal 
macrophages isolated from control (CM) and methimazole-treated 
(MM) mice. The cells were stimulated in vitro with lipopolysaccharide 
(LPS, Ipg/million) andphorbol 12-myristate 13-acetate 4-o-methylester 
(TPA, 200 nM) for 1 h. The results are expressed as means 土 standard 
deviation ***p < 0.001. 
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Discussion 
Methimazole, a commonly used antithyroid drug, has been reported to exert 
immunosuppressive effects on both macrophages and lymphocytes (Weetman et al., 
1984; 1986). However, whether this is a direct effect remains controversial (Bagnasco 
et al., 1990; Balazs et al” 1986; Weetman et a/., 1986). Liu and his colleagues (1989, 
1991) showed that MMI-Seated mice had lower phagocytic and tumoricidal activities. 
The molecular basis for the tumoricidal activity of activated macrophages is not 
clearly known, but their secretory products, such as TNF, RNI and ROI may play an 
important role in this process (Ding et aL, 1988; Kilbourn et a/., 1984; Nacy et aL’ 
1991; Nathan & Hibbs, 1991; Urban et al” 1986). This study further demonstrated 
that in vivo MMI treatment interfered with TNF gene expression and production of 
RNI and superoxide anion following LPS stimulation, which may account for the 
diminished tumoricidal activity in MMI-treated mice. 
TNF was first discovered as a soluble factor that induced haemoniiagic 
necrosis of tumour in animals (Cai'swell et al., 1975) and exerted cytotoxic effect to 
some tumour cell lines in vitro (Mattews et al” 1978; Sugennan et al” 1985). Recent 
studies indicate that there is a wide variety of biological activities of TNF, for 
instance, TNF acts on various cell types and tissues by stimulating the production of 
interferon-l32 from fibroblasts (Sugennan et a1,, 1985; Kohase et <7/., 1986), the release 
of interleukin-1 from endothelial cells (Nawroth et al” 1986; Collins et al” 1986)，and 
the activation of lymphocytes (Scheurich et aL, 1987) and polymorphonuclear 
neutrophils (Shalaby 过以/., 1985). Moreover, being a member of the cytokine 
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network, TNF also acts in conceit with other cytokines to affect the functions of 
macrophages and neutrophils (Chouaib et al” 1988; Shalaby et aL, 1985). Although 
the detailed regulatory mechanisms remain largely unknown, TNF plays a central 
regulatory role in the antimicrobial and tumoricidal activities of macrophages in 
synergy with interleukin-1 (Old et ^//., 1987), inteiieukin-2 (Chouaib et aL, 1988; 
StrieterV "/., 1989b), interleukin-4 (Humbert & Winsor, 1990; Nacy et al., 1991) and 
gamma-interferon (Davila et d ” 1990). The decrease in TNF transcription in 
macrophages or circulating TNF in the serum of MMI-treated mice might interfere 
with the normal immune response of the animal. 
In this chapter, MMI-treated mice showed a lowered ability to produce TNF 
protein and mRNA in response to either in vivo or in vitro LPS treatment, but the 
kinetics of TNF gene expression were found to be remarkably different. TNF 
bioactivity and mRNA showed a decrease 1 h after in vivo LPS stimulation, while the 
levels of TNF protein and mRNA were maintained during the first four hours in the 
case of in vitro LPS treatment (Figure 2.1 and Figure 2.4). A similar observation was 
also reported by Strieter and his colleagues which showed that TNF production in 
human whole blood declined at 4 h after in vivo LPS treatment while the level ofTNF 
bioactivity in human alveolar macrophages and peripheral blood monocytes increased 
even 18 h after in vitro LPS treatment (Stricter et al” 1989a,b). A plausible 
explanation for such a discrepancy in TNF production is that different populations of 
macrophages or macrophages at different differentiation stages in the body showed 
different responsiveness to immunostimulants (Strieter et al.y 1989a, 1990). 
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Reactive nitrogen intermediates (RNI) exhibit their cytotoxicity against target 
tumour cells by suppressing cellular mitochondrial respiration (Amber et aLr 1991; 
Kilbourn er al” 1984; Mauel et al” 1991; Takema er al” 1991), while ROI appear to 
be important components of the oxygen-dependent killing of ingested microbes by 
phagocytes (Fridovich, 1976; Nathan et al” 1980). Generation of these highly reactive 
intermediates is important for tumour killing and for macrophage antimicrobial activity 
(Henricks et al., 1987; Hibbs et al” 1988; Keller et aL’ 1990a; Murray & Cohn,;1979). 
Macrophages generate oxygen free radicals into the extracellular milieu through the 
respiratory burst enzyme, reduced nicotinamide-adenine-dinucleotide phosphate 
oxidase, which can be activated by TPA (Laurent et aL, 1991; Slosman et al” 1990) 
or TNF (Schreck & Baeuerle，1991). The generation of ROI in CM and MM was 
unlikely due to an inductive effect of TNF since at 10 pM TPA, no TNF production 
was observed (unpublished data). Generation of RNI and expression of tumoricidal 
activity appear to depend on the flow of L-arginine through both the Ca^-independent 
nitric oxide synthase and the arginase pathways which are usually triggered by heat-
killed bacteria and LPS in macrophages (Hauschildt et al” 1990; Keller et aL, 1991; 
Kolb & Kolb-Bachofen, 1992). The production of RNI can be augmented if the 
macrophages are priorly primed with IFNy (Amber 1991; Mauel ^ al., 1991), 
an active component in crude lymphokines (Amber et al” 1991), This synergistic RNI 
production was also observed in both CM and MM in response to LPS and crude 
lymphokines (Figure 2.7)，but the latter failed to produce similar RNI in response to 
LPS alone as well as LPS plus crude lymphokines, indicating that the normal 
functions of MM was impaired. 
40 
Chapter 3 Effect of /w Vivo Methimazole Treatment on the 
Functions of Lymphocytes 
Introduction 
Lymphocytes are produced in the primary lymphoid organs (thymus and adult 
bone marrow), and then migrate into the secondary lymphoid tissues (spleen, lymph 
nodes and tonsils) via lymphoid cii'culation. Based on the morphological 
characteristics and cell surface receptors, lymphocytes can be divided into two major 
functional populations, namely B and T lymphocytes. The latter are further divided 
into cytotoxic T cells, helper T cells and suppressor T cells according to their surface 
characteristics. B lymphocytes are responsible for humoral immune response while 
T lymphocytes and macrophages cooperate in the direct destruction of pathogenic 
organisms. 
When lymphocytes are stimulated by either antigens or mitogens, the cells 
differentiate into lymphoblasts, and produce a wide array of lymphokines such as 
interleukins, interferons and tumour necrosis factors, which are important in mediating 
a variety of processes in host defense, inflammation and response to injury (Arai et 
al” 1990; Old； 1987). In response to mitogens such as lipopolysaccharide (LPS), 
concanavalin A (Con A) and phytohemagglutinin (PHA)，lymphocytes secrete gamma-
interferon (IFNy) and interleukin-2 (IL-2). These soluble factors are critical in cell 
communication and act in concert with other cytokines to affect other cell functions 
(Ki-onke et al., 1985; Strieter et al” 1989b). 
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Interleukin 2 (IL-2) 
IL-2 was originally described as T cell growth factor that promoted the 
proliferation of T lymphocytes. The IL-2 molecule is a single polypeptide chain of 
133 amino acid residues. The molecule is O-glycosylated at residue 3 which is 
threonine, and an essential disulphide link is found between residues 58 and 105. A 
single gene exists for IL-2 so that differences in molecular species are entirely 
attributable to different degrees of glycosylatioit IL-2 is secreted mainly by helper 
T cells following stimulation by binding of an antigen or a plant lectin (Con A and 
PHA) to surface receptors resulting in proliferation of these cells, enhanced secretion 
of lymphokines, elevated expression of membrane receptors for other growth factors 
and expression of class I IMHC molecules (Arai et al” 1990), It has been shown that 
IL-2 binds to its receptors on the plasma membrane of B lymphocytes for their full 
differentiation into antibody secreting plasma cells (Meidema & Milief，1985; Robb， 
1984). The IL-2 receptor consists of two polypeptide chains with differing binding 
affinities. A 75 kDa protein binds IL-2 with a lower affinity while a 55 kDa protein 
binds IL-2 molecules with a much higher affinity (Zhu et a.L, 1989; Smith, 1987). IL-
2 also increases the cytotoxic capacity of natural killer (NK) cells and TNF gene 
expression in macrophages (Trinchieri ^r aL, 1984; Strieter et al., 1989b). 
Interferon-y (IFNy) 
In 1957, Isaacs and Lindnemann discovered a factor produced by virus-infected 
cells that transferred virus resistance to fresh tissues for which they coined the term 
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interferons (IFNs). IFNs were firstly discovered by its antiviral activity and then 
recognized as a potent modulator of immune response. Based on structural 
differences, there are several types of IFNs, including IFNa, IFNB and IFNy. IFNa, 
IFNB are produced in most nucleated cells when infected with a virus. IFNy is 
mainly secreted by helper (CD 4) T cells in response to activation by an antigen or 
a plant lectin but cytotoxic T cell (CD 8) and natural killer cells also constitute to its 
production (van Wauwe et al., 1980; van den Eertwegh al” 1991). It acts as a very 
potent macrophage-activating factor for the killing of tumour cells and intracellular 
parasites by producing effective molecules such as TNF, RNI and ROI (Davila 打 al., 
1990; Mauel (7/., 1991). 
In chapter 2, the activity of macrophages from MMI-treated mice were 
suppressed, and in this chapter, the effect of in vivo MMI treatment on lymphocytes 
was estimated. The levels of IL-2 and IFNy in crude lymphokines, as well as the 
mitogenic responses of splenocytes from MMI-treated mice were measured. In 
addition, Liu and his colleagues (1989) have shown that crude lymphokines produced 
from splenocytes of MMI-treated mice had a weaker ability in activating macrophages 
to kill P815 mastocytoma cells in vitro. As TNF and RNI are involved in the 
tumoricidal activity of macrophages (Phillips et al” 1990), their secretions in response 
to crude lymphokines from MMI-treated mice were compared with their respective 
controls. 
43 
Materials and Methods 
MMI treatment. 
Three groups (25/group) of male C57BL/6 mice, aged 8 - 10 weeks, were 
provided with 0.1% methimazole (MMI, Sigma, M8506, St. Louis) in drinking water 
ad libitum for 2，4 and 6 weeks. These 3 groups of MMI-treated animals were used 
to prepare crude lymphokines, and the macrophages for bioassays were only collected 
from mice subjected to 6 weeks of MMI-treatment. Twenty-five age-matched mice 
which received tap water were used as controls. The animals were housed under 
normal laboratory conditions (21 士 20C，12/12- light/dark cycle) and maintained on 
standard rodent chow. 
Preparation of splenocytes 
Mice were sacrificed by cervical dislocation, and the spleens were aseptically 
removed. Splenocytes were obtained by gently pressing the spleens through a 100-
mesh stainless steel sieve to obtain a single cell suspension. The tissue debris was 
removed by sedimentation, and the cells were washed, counted and resuspended in 
RPMI supplemented with 10% fetal bovine serum, 0.01M HEPES, streptomycin 
(lOOpg/ml) and penicillin (100 IU/ml). 
Proliferative response of splenocytes to mitogens 
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Splenocytes (5 x 105 cells/0.1 ml/well) were cultured in the presence of a serial 
dilution of Con A or LPS in 96-well flat-bottom microtiter plates at 37°C in a 
humidified atmosphere of 5% C02 for 42 h. The cells in each culture well were 
pulsed with 0.5pCi/10pl of 3H-methylthymidine (3H-TdR, specific activity 5 Ci/minole, 
Amersham, England) for 6 h and thereafter were harvested onto a glass Fiber filter 
with a cell harvester (Titertek, Flow Laboratories, England). The radioactivity was 
measured using a Beckman scintillation counter and the mitogenic response of 
lymphocytes was expressed as mean counts per minute (cpm). 
Preparation of crude lymphokines 
Suspensions of splenocytes (1 x 107 cells/ml) from normal and MMI-treated 
mice were cultured in a 75 cnr culture flask (Falcon, 3024, USA) in the presence of 
10 pg/ml Con A for 3 h. The culture medium was removed, and the spleriocyte 
monolayer was rinsed gently with warm PBS containing Ca4"*" (0.133 g/1) and Mg^ 
(0.1 g/1) to remove excess Con A, The cells were further incubated in 20 ml of fresh 
supplemented RPMI for 24 h at 37°C. After incubation, the cell-free culture medium 
was sterilised by passing through a 0.22 pm millipore filter (Millipore, GSWP, 04700) 
and the lymphokine-containing medium was collected for the activation of 
macrophages. For the experiment in RNI production, splenocytes were cultured in 
DMEM without phenol red (Simga, D2902, St. Louis). 
IL-2 bioassay 
45 
The content of IL-2 in crude lymphokines was determined according to the 
method described by Gillis and his colleagues (1978). Murine IL-2 dependent 
cytotoxic T lymphocytes (CTLL 2) were purchased from American tissue cell culture 
(ATCC, USA) and maintained in supplemented RPMI containing 40 % rat growth 
factor. Before use, the GTLL 2 cells were washed free of growth medium and 
resuspended in supplemented RPMI at 4 x 105 cells/nil. Aliquots (0.1ml) of the cells 
were cultured in 96-well microtiter plates in the presence of a serial dilution of crude 
lymphokines at 37°C in a humidified atmosphere of 5 % C02 . The cells were 
incubated for 18 h, and pulsed for 6 h with 0.5 pCi of 3H-TdR/10 pl/well (specific 
activity 5 Ci/mmole, Amersham, England). The cells were harvested onto a glass 
fiber filter with a cell harvester (Titertek, Flow Laboratories, England), and tlie 
radioactivity was measured using a Beckman scintillation counter. Serial dilutions of 
recombinant IL-2 (Peninsula Laboratory, USA) were applied in parallel to construct 
a standard curve from which the levels of IL-2 (U/ml) in the crude lymphokine 
samples were calculated. 
Preparation of rat growth factor for CTLL-2 culture 
The rat growth factor for CTLL-2 was prepared according to the method 
recommended by ATCC. B r i e f l y , splenocytes were obtained from Sprague-Dawley 
rats weighing 200 g, washed, counted and resuspended in supplemented RPMI. 
Suspensions of splenocytes (1 x 107 cells/ml) were cultured in a 75 cm2 culture flask 
in the presence of Con A (5 pg/ml) for 48 h. The cell-free culture medium was used 
as the source of rat growth factor. The Con A was neutralized by 20 mg/ml a -
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methyl-D-mannoside (Sigma, M6882, St. Louis), and the rat growth factor preparation 
was stored at -20°C before use. 
IFNy content in crude lymphokines 
The IFNy content in crude lymphokines was determined by the InterTest 
Mouse IFNy kit (Genzyme, 155700, USA) according to the method provided�by the 
manufacturer. Briefly, a 96-well microtiter plate was coated with a hamster 
monoclonal antibody specific for mouse IFN7 and incubated overnight at 4�C. The 
plate was washed with washing buffer (PBS + surfactant) and nonspecific binding was 
blocked by blocking buffer for 2 h at 37°C The plate was washed, and 200 pi of 
crude lymphokines and samples of mouse IFNy standards were added to each well of 
the microtiter plate. After 2 h incubation at room temperature, the plate was washed 
and incubated with the secondary antibody (a goat anti-hamster polyclonal antibody) 
to increase the binding affinity with the peroxidase-conjugated donkey anti-goat 
antibody for 1 h. The plate was rinsed 3 times between the steps with washing buffer. 
Finally, the peroxidase., activity was^; detennined by using a peroxide/o-
phenylenediamine dihydrochloride (OPD) substrate solution, Tlie peroxidase acts on 
the substrate to produce a colour change at 492 nm and the colour reaction was 
stopped after 5-10 min by addition of 2 N sulphuric acid. The change in absorbance 
was quantiated by an ELISA reader (Bio Rad, 3550, USA). The concentration of 
IFNy in the crude lymphokines was determined from a standard curve constructed 
. u s i n g known concentrations of recombinant IFNy provided by the manufacturer. 
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Collection of Macrophages 
The peritoneal macrophages were collected by the method described in Chapter 
2. Unless specified, all macrophages to be used for bioassay were collected from 
mice subjected to MMI-treatment for 6 weeks, and those receiving tap water served 
as the control. 
Production of TNF and TNF bioassay 
The production of TNF and its bioassay were performed by the method 
described in chapter 2，with the exception that the macrophages (2 x 106 cells/well) 
were pre-treated for 24 h at 37�C with crude lymphokines from control (CLK) mice 
and mice treated with MMI for 6 weeks (MK6) (dilution 1:1，v/v). The cells were 
then washed and stimulated with LPS (1 pg/ml) for 0，1，2，4 and 20 h. This assay 
measured the level of the macrophage activating factor in the lymphokines prepared 
from both control and MMI-treated mice. 
Production of reactive nitrogen intermediates (RNI) 
The in vitro production of RNI by crude lymphokines stimulated peritoneal 
macrophages was estimated by the level of N02 ' which was measured according to the 
method described in chapter 2. Adherent macrophages (2 x 106 cells) were stimulated 
with LPS (10 ng/ml) and LPS (10 ng/ml) together with crude lymphokines (dilution 
1:1，v/v) from control mice and mice subjected to MMI treatment for 2, 4 and 6 
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weeks (MK2, MK4, MK6 respectively). 
Analysis of Data 
Results are expressed as means 土 standard deviation. Student's t test was used 
to compare the difference between control and MMI-treated groups. Asterisks 
indicated level of significance, < 0.05, < 0 . 0 1 ， < 0.001. 
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Results 
Proliferative responses of splenocytes to mitogens 
In this experiment, the mitogenic responses of splenocytes to Con A and LPS 
were studied. Generally, splenocytes from normal mice showed stronger mitogenic 
responses to Con A and LPS (peak at 20 pg/ml and 4 pg/ml respectively) and thus had 
a significantly higher (p < 0.01) incorporation of 3H-thymidine when compared with 
splenocytes from MMI-treated mice (Figure 3.1 and 3.2). The reduction in mitogenic 
responses of splenocytes from MMI-treated mice to Con A (20 pg/ml) became more 
prominent as the duration of MMI treatment increased. 
IL-2 production 
IL-2 was measured by the IL-2 dependent cell line, CTLL 2，and its 
concentration in the crude lymphokines was calculated according to the standard curve 
constructed from 3H-thymidine uptake of CTLL 2 cells in the presence of serial 
concentrations of recombinant IL-2 (Figure 3.3). Normal crude lymphokines contained 
12.81 U/ml IL-2, and the splenocytes from MMI-treated mice showed a weaker ability 
in producing IL-2 in response to Con A stimulation (Table 3.1). Only half the amount 
of IL-2 (6.65 U/ml) was measured in the crude lymphokines from mice treated with 
MMI for 2 weeks. The extent of reduction also become more prominent (p < 0.001) 
when the duration of MMI treatment increased. 
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IFNy content in crude lymphokines 
A standard curve constructed using known concentrations of IFNy is shown 
in Figure 3.4. The IFNy levels in crude lymphokines from normal and MMI-treated 
mice were calculated from this standard curve and the results are listed in Table 3.1. 
Crude lymphokines from MMI-treated mice had a significantly lower (p < 0.001) 
content of IFNy when compared with that from normal mice (184 pg/ml). Only 70 
%’ 45 %, 8 % of the normal IFNy value were measured in the crude lymphokines of 
mice treated with MMI for 2’ 4 and 6 weeks respectively. This decrease was 
dependent on the duration of MMI treatment. 
TNF production 
Figure 3.5 shows the kinetics of in vitro TNF production by lymphokine-
activated macrophages following LPS stimulation. Macrophages produced TNF at the 
peak level at 4 h and decreased to the basal level at 20 h. Pretreatment of 
macrophages with crude lymphokine from both control and MMI treated mice did not 
alter the pattern of TNF production during the first 4 h (Figure 3.5). However, crude 
lymphokines from normal mice increase the production of TNF even at 20 h whereas 
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Figure 3.1 The-mitogenic response of splenocytes isolated from control (CTL) and 
methimazole-treated (MMI) mice to various concentrations of 
Concanavalin A (Con A). After stimulation for 48 h, the cells were 
pulsed with 3H-thymidine. The data are expressed as means 土 standard 
deviation (n=6). *p < 0.05, **p < 0.01. 
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Figure 3.1 The- mitogenic response of splenocytes isolated from control (CTL) and 
methimazole-treated (MMI) mice to various concentrations of 
Concanavalin A (Con A). After stimulation for 48 h, the cells were 
pulsed with 3H-thymidine. The data are expressed as means 土 standard 
deviation (n=6). *p < 0.05, **p < 0.01. 
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Figure 3.2 The mitogenic response of splenocytes isolated from control (CTL) and 
inethiinazole-ti-eated (MMI) mice to various concentrations of 
lipopolysaccharide (LPS). After stimulation for 48 h, the cells were 
pulsed with 3H-thymidine. The results are expressed as means 士 
standard deviation (n=6). Asterisks indicated the level of significance, 
*p < 0.05, **p < 0.01. 
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Figure 3.3 The standard curve constructed from known concentrations of 
recombinant interleukin-2 (IL-2). The results are expressed as means 
士 standard deviation (n=6). 
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Figure 3.4 The standard curve constructed using known concentrations of 
recombinant gamma-interferon (IFNy). The results are expressed as 
means 土 standard deviation (n=6). 
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Figure 3.5 In vitro production of tumour necrosis factor (= % inhibition of L929 
cell growth) by peritoneal macrophages primed with crude lymphokines 
from control (CLK) mice or methimazole-treated (MK6) mice for 24 
h and then followed by LPS stimulation for 1，2，4 and 20 h. The 
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Figure 3.6 Production of reactive nitrogen intermediates (RNI), as measured by the 
level of nitrite (pM/million cells), by peritoneal macrophages isolated 
from both control (CM) mice and methimazole-treated (MM) mice. 
The cells were stimulated in vitro with LPS (10 ng/ml), crude 
lymphokines (LK) and a combination of LPS and crude lymphokines 
from control mice (LPS + CLK), mice after 2 weeks (LPS + MK2), 4 
weeks (LPS + MK4) or 6 weeks (LPS + MK6) of methimazole 
treatment for 20h. The results are expressed as means 士 standard 
deviation (n=6). *p < 0.05, **p < 0.01 
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MMI treatment (wk) IL-2 (U/ml) IFNy (pg/ml) 
0 12.81 土 3.98 184.16 土 9.05 
2 6.65 ± 1.75*** 132.59 ± 4.38*** 
4 6.34 土 1.04*** 83.21 士 
6 4.11 士 0.73*** 16.96 ± 8.75*** 
Table 3.1 The in vitro production of interleukin-2 (IL-2) and gamma-interferon 
(IFNy) by concanavanlin A (Con A)-stimulated splenocytes isolated 
from control mice，and mice after 2, 4 or 6 weeks of methimazole 
treatment. The results are expressed as means 土 standard deviation 
( 1 1 二 6 ) < 0 , 0 0 1 . 
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Discussion 
Interleukin-2, which was formerly named T cell growth factor, has been found 
to induce the proliferation of T lymphocytes (Dinarell et al” 1987), and the cytotoxic 
capacity of natural killer cells and monocytes (Trinchieri et al., 1984), In response to 
stimulation with Con A, a potent stimulator of T lymphocytes which mimics the effect 
of antigens in stimulating proliferation, helper T lymphocytes produce IL-2 which in 
turn induces the secretion of IFNy from lymphocytes in an autocrine fashion (Kronke 
et al” 1985). IFNy has been demonstrated to be an endogenous mediator that acts as 
a priming agent for TNF in cell-mediated immune processes (Strieter et al., 1989b; 
Arai et al., 1990; Davila et al” 1990). More recently, in synergy with LPS, IFNy was 
found to trigger the release of reactive nitrogen intermediates form activated 
macrophages (Takema et al” 1991; Mauel et al” 1991). 
It has been suggested that methimazole (MMI) showed an immunosuppressive 
effect in vitro (Okabe et al., 1983). Liu and his colleagues (1989) found that after in 
vivo treatment of MMI, the concentration of macrophage activating factor in crude 
lymphokines was lowered. The results in the present study also agree with their 
findings and further demonstrate that crude lymphokines from MMI-treated mice 
cannot fully activate macrophages to produce TNF and RNI, in comparison with the 
normal lymphokines (Figures 3.5 and 3.6). Their macrophage activating ability 
seemed to decrease with the duration of MMI treatment (Figure. 3.6). 
There is now evidence demonstrating that the macrophage activating factor 
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(MAF) in crude lymphokines is attributed mainly to IFNy (Nathan et al” 1983; 
Svedersky et a I., 1984), and its decrease in production by splenocytes may underlie 
the poor activation of macrophages from MMI-treated mice. The bioassay with 
CTLL-2 cells also showed that the production of IL-2 by lymphocytes from MMI-
treated mice decreased at least by 50 % (Table 3.1)，and this may account for the 
decrease in TNF production from macrophages (Strieter et al., 1989b). Since IL-2 is 
also a soluble factor in crude lymphokines which support the proliferation of activated 
T cells in culture (Morgen et al” 1976), it is therefore expected that the mitogenic 
responses of splenocytes from MMI-treated mice to Con A and LPS were significantly 
lower than theii* respective controls (Figures 3.1 and 3.2)‘ The decrease in lymphocyte 
proliferation and IL-2 production caused a decline in IFNy level in the crude 
lymphokines (Table 3.1) which, in turn, affected the production of TNF and RNI from 
macrophages (Figures 3.5 and 3.6). 
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Chapter 4 The Lack of Demonstrable Effects of In Vitro 
Methimazole Treatment on Macrophages and 
Lymphocytes 
Introduction 
Thionamide drugs including methimazole (MMI) and propylthiouracil (PTU) 
have been clinically prescribed to treat patients with hyperthyroidism of both 
autoimmune and non-autoimmune origins, as these drugs inhibit thyroid peroxidase-
catalyzed iodination of thyroglobulin (Leer et al., 1991; Okabe et aL, 1984). It has 
been suggested that these drugs also relieve the diseases by a direct 
immunomodulatory influence (DeGroot, 1977; Hallengren et al” 1980; Bagnasco et 
al" 1990). Several investigators reported that the levels of thyroid-stimulating 
immunoglobulins and lymphocyte infiltration into the thyroid gland were suppressed 
after treatment with the antithyroid drugs (Aoki et aL, 1979，Beck et al” 1973). 
The evidence for an action of antithyroid drugs on immune responses, however, 
appeared to be controversial. MMI was reported to stimulate proliferative response 
of human lymphocytes (Hallengren et al., 1980; Okabe et al., 1983，1984), whereas 
contrasting results demonstrated that MMI exerted immunosuppressive effects both in 
vitro (Balazs ^ ¢//., 1986) and in vivo (Davies et al” 1984; Liu et al” 1989) on cell-
mediated immunity. In addition, some studies failed to provide evidence of any direct 
effect of MMI on cell-mediated cytotoxicity and T lymphocytes (Weetman et al., 
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1985; Bagnasco et al” 1990). 
In vivo treatment with MMI elicited immunosuppressive effects on 
macrophages (Chapter 2) as well as lymphocytes whose crude lymphokines further 
interfere with normal macrophage functions (Chapter 3). In order to investigate the 
possibility of a direct action of MMI on the cells, macrophages and lymphocytes were 
cultured in the presence of various concentrations of MMI, and the production of TNF, 
RNI and superoxide anion from macrophages, and the mitogenic responses of 
splenocytes to different mitogens were also studied. 
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Materials and Methods 
Collection of Macrophages and in vitro MMI treatment 
Normal macrophages were collected according to the method described in 
Chapter 2. Once the macrophages adhered onto the culture plates, they were 
incubated with a serial concentration of MMI (0，1，10, 100，1000，10000 pM>for 24 
h，and were thereafter activated for bioassays. 
... ' .. - ‘ “� :i . ,. .. ‘ “ :樣.、.《，.'* . . . . . •‘ 
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Cell viability 
The viability of cells after incubation with MMI solution was determined by 
the neutral red staining methods (Klostergaard et al., 1987; Saotome et al., 1989). 
Briefly, after incubation with MMI solutions for 24 h, macrophages were stained with 
neutral red solution. Excess dye was removed and the cells were washed several 
times with PBS containing Ca^ and Mg"^. The dye taken up by the cells was 
extracted by acidic alcohol (1% acetic acid in 50% alcohol). The viability of the cells 
was measured by absorbance at 540 nm using a microplate ELIZA reader. 
Production of TNF and TNF bioassay 
After incubation with different concentrations of MMI for 24 h，the 
macrophages were washed and their ability to produce TNF in vitro was measured by 
L929 cytotoxicity bioassay (Chapter 2). 
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Production of reactive nitrogen intermediates (RNI) 
In vitro production of N02" by macrophages with in vitro MMI pre-treatment 
was measured according to the method described in Chapter 2. 
Proliferation of splenocytes to mitogens 
The splenocytes were collected by the method described in Chapter 3. The 
suspension of splenic lymphocytes was cultured in a 96-well microtiter plate together 
with MMI which was added to yield a final concentrations of 1-1000 pM. The 
mitogenic responses of lymphocytes were then determined (Chapter 3). 
Analysis of Data 
Results are expressed as means 土 standard deviation. Student's t test was used 
to compare the difference between various groups. Asterisks indicate the level of 




The cytotoxicity of MMI on macrophages is shown in Figure 4.1. There is no 
significant change in the viability of macrophages, as detennined by neutral red 
staining method, when the cells were exposed to MMI solutions ranging from 1 to 
1000 pM. A significant decrease (from 100 % to 85.54 % for neutral red, p < 0.05) 
in cell viability was observed only when the MMI concenti^ation was increased up to 
10000 pM, MMI at 1-1000 pM MMI was not toxic to the macrophage culture. 
TNF production 
After in vitro MMI pre-treatment for 24 h, the macrophages were stimulated 
with LPS to produce TNF which corresponded to the percent inhibition of L929 cell 
growth. Figure 4.2 shows that TNF production was dependent on the duration of LPS 
treatment. During the first 4 h of LPS stimulation, MMI of different concentrations 
( 1 - 1 0 0 0 jjM) did not interfere with TNF production. 
RNI production 
The macrophages were stimulated by LPS, crude lymphocytes, or LPS plus 
crude lymphokines to produce RNI, which was measured by the level of their stable 
metabolite, N02 '. Figure 4.3 shows, MMI at noivcytotoxic concentrations (1-1000 
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pM) did not interfere with RNI production, no matter what the stimulant was used. 
The only significant decline (p < 0.01) in RNI release, however, was observed in the 
culture with extremely high concentration (10000 pM) of MMI, which may be due to 
the cytotoxic effect of the drug (Figure 4.1). 
02" production 
In this experiment, after 1 h stimulation by TPA, normal macrophages 
produced 6.19 pM 02" per million cells (Figure A A). MMI (l-1000pM) showed no 
effect on superoxide anion production, except in cells exposed to 10000 pM MMI, a 
significant decrease (p < 0.05) in superoxide anion release in cells was observed. This 
was again due to a direct cytotoxic effect of MMI on macrophages. 
Splenocyte proliferative responses 
Normal splenocytes started to proliferate in the presence of 2.5 pg/ml Con A 
and 0.25 pg/ml LPS respectively, reaching maximum levels at 10 pg/ml for Con A and 
2 pg/ml for LPS and declining thereafter (Figure 4.5 and 4.6). Similar growth patterns 
were observed in lymphocytes in response to both mitogens. 
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Figure 4.1 The cytotoxic effect of methimazole (1-10000 pM) on the peritoneal 
macrophages as determined by the neutral red staining method. The 
results ai-e expressed as means 土 standard deviation (n==6). < 
0.001. 
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Figure 4.2 Production of tumour necrosis factor (TNF) by mouse peritoneal 
macrophages which had been treated with various concentrations of 
methimazole (1-1000 pM) for 24 h, and then stimulated with 
lipopolysaccharide (LPS) for 1，2 and 4 h. The results are expressed 
as means 土 standard deviation (n=6)/ j 
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Figure 4.3 Production of reactive nitrogen intenriediates (RNI)； as measured by the 
level of nitrite (pM/inillion cells) by mouse peritoneal macrophages 
which had been treated with various concentrations of methimazole (1-
10000 pM) for 24 h, and then stimulated with lipopolysaccharide 
(LPS), crude lymphokines (LK) and a combination of LPS + LKfor 20 
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Figure 4.4 Production of reactive oxygen intermediates (ROI), as estimated by the 
level of superoxide (pM/million cells), by mouse peritoneal 
macrophages which had been treated with various concentrations of 
methimazole (1-10000 pM) for 24 h, and then stimulated with TPA for 
1 h. The results are expressed as means 土 standard deviation (n=6). 
**p < 0.01. 
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Figure 4.5 The mitogenic response of mouse splenocytes to various concentrations 
of concanavalin A (Con A) and methimazole. After stimulation for 42 
h, the cells were pulsed with 3H-thymidine for 6 h. The 3H-thymidine 
uptake by lymphocytes is expressed as means 土 standard deviation 
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Figure 4.6 The mitogenie response of splenocytes to different combinations of 
lipopolysaccharide (LPS) and methimazole. After stimulation for 42 
h, the cells were pulsed with 3H-thymidine for 6 h. The results are 
expressed as means 土 standard deviation (n=6). 
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Discussion 
The immunosuppressive effects of MMI in vivo are well-documented. It has 
been shown that MMI decreased the autoantibody level in patients with Grave's 
disease as well as in rats with experimental autoimmune thyroiditis (Young et aL, 
1976; Rennie er a/” 1983). The natural killer cell activity in euthyroid patients and 
tumoricidal activity of macrophages in mice were also depressed after in vivo MMI 
treatment (Wang et aL, 1988; Kinoshita et al., 1991; Liu et aL, 1989). However, there 
have been conflicting evidences on the immunomodulatory action of MMI in human 
beings and mice (Aguoyo et al.’ 1988，Balazs et al” 1986). Contradictory results have 
been reported on interleukin-2 production in lymphocytes after in vitro MMI treatment 
(Weetman, 1985; Eisenstein et a I., 1988; Bagnasco et «/„1990). 
A significant decrease in the production of TNF, RNI and ROI by macrophages 
as well as production of IL-2 and IFNy by lymphocytes isolated from MMI-treated 
mice has been demonstrated in Chapter 2 and 3. TNF, RNI and 02" are important for 
the tumoricidal and microbicidal activities of macrophages (Ding et ^//., 1988; Keller 
et al, 1990b; Muiray et aL, 1979). IL-2 and IFNy are essential lymphokines involved 
in the activation of lymphocytes and macrophages. The proliferative response of 
splenocytes to mitogens reflects the normal functioning of the cell-mediated and 
humoral immune systems. It was the intent of this study to investigate whether MMI 
imposed a direct action on the immune cells such as lymphocytes and macrophages 
or a secondary effect on the immune system by altering the thyroid hormone balance 
of the mice. This study showed that MMI in vitro did not interfere with the 
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production of TNF, RNI and 02 ' nor the mitogenic responses of splenocytes to LPS 
and Con A. These results coincide with other findings that the immunosuppressive 
effects of MMI are not due to a direct drug effect on immune cells (Bagnasco et. aL, 
1990; Aguayo et aL, 1988). 
As far as MMI is concerned, the present data does not support those of Wilson 
and his colleagues (1990) which claimed that MMI affected the function of 
monocytes, and T and B lymphocytes. MMI at the concentration range from 1 to 
lOOOpM exerted no effect on splenocytes and macrophages, although macrophages but 
not lymphocytes accumulated 35S-methimazole because of the presence of peroxidase 
enzymes (Weetman et at., 1984). It is worthy to mention that the immunosuppressive 
effect of MMI should be clearly distinguished from the toxic effect of the drug 
because of the high drug concentration utilized (Okabe ^ (7/., 1983). Besides, //i vivo 
and in vitro effects of MMI are somewhat different form each other. Liu and his 
colleagues (1991) showed that MMI in vivo caused a decrease of TNF production and 
lysosomal enzyme activity in macrophages. This decline, however, was due to MMI-
induced hypothyroidism, and not to the drug itself because the decrease in TNF 
production could be normalized after thyroid honnone replacement (Chapter 5). 
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Chapter 5 Effect of Thyroid Hormone Replacement on the 
Immune Response of Methimazole-Treated Mice 
Introduction 
It has recently been emphasized that autoimmune thyroid diseases such as 
Graves' disease and Hashimoto's disease, involve similar immunologic abnormalities 
in T lymphocytes (Bunnan & Baker, 1985; Weetman et al., 1984a). These findings 
arouse the interest in the relationship between thyroid hormones and the immune 
system under both normal and pathologic conditions. Patients with severe 
hypothyroidism have been reported to be more susceptible to infectious agents. This 
may be closely associated with the decreased bactericidal capacity of neutrophils 
(Palmblad et al” 1981) and diminished lysosomal enzyme activity in macrophages 
(Starling & Weese, 1985). In addition, hypothyroid animals were found to have a 
reduced total white blood cell counts and number of lymphocytes (Scott and Glick, 
1987)，antibody response (Fabris, 1973), proportion of suppressor T cells in the spleen 
(Pacini et aL, 1983) and blastogenic response of the lymphocytes (Chatterjee & 
Chandel, 1983). All these findings suggest that the immune response is weakened in 
hypothyroidism. 
The mechanism of increased susceptibility to infections in severely hypothyroid 
patients has not been fully elucidated. Liu and his colleagues (1989) have 
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demonstrated that MMI-treated mice have a lower level of circulating thyroid 
hormones. Macrophages and lymphocytes are important for both cell-mediated and 
humoral immunities, and chapters 2 and 3 have that the production of TNF, RNI and 
02" from macrophages as well as the mitogenic responses of lymphocytes in MMI-
ti'eated mice were suppressed. The objective of the first part of this chapter was 
therefore to correlate levels of serum and cellular thyroid hormones with the functions 
of immune cells while the second part was to investigate whether these abnormalities 
of the immune cells could be normalized by thyroid hormone replacement. 
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Materials and Methods 
MMI treatment and thyroid hormone replacement. 
Two groups (25/group) of male C57BL/6 mice, age 8 - 10 weeks, were treated 
with 0.1% methimazole (MMI, Sigma 8506, USA) in drinking water ad libitum for 
6 weeks. During the last week of MMI treatment/ one group of mice received 
subcutaneously injection of T4 (2.8 pg/mice/day) for 6 consecutive days. Twenty-five 
age-matched mice received tap water and were used as controls. The animals were 
housed under normal laboratory conditions (21 土 2�C，12/12- light/dark cycle) and 
maintained on standard rodent chow. After MMI treatment for 6 weeks, serum 
samples, peritoneal macropliages and lymphocytes were collected from mice and the 
levels of thyroid hormones (T3 and T4) were measured to determine their thyroid 
status. 
Collection of splenocytes and preparation of crude lymphokines 
Splenocytes were collected from normal mice (CS), MMI-treated mice (MS) 
and mice with T4 replacement (TS) according to the method described in Chapter 3. 
Crude lymphokines were prepared from normal mice by the method described in 
Chapter 3. 
Collection of Macrophages 
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Macrophages were collected from normal (CM), MMI-treated mice (MM) as 
well as mice with T4 replacement (TM) by the method described in Chapter 2. 
Production of TNF and TNF bioassay 
The in vitro production of TNF was assessed according to a method similar to 
that described in Chapter 2. CM, MM and TM were stimulated with LPS (1 |ig/ml) 
for 0，1，2 and 4 h, and the TNF-containing medium was collected for TNF bioassay. 
Production of RNI 
CM, MM and TM were stimulated with different stimulants and the production 
of RNI, as indicated by the N02" level, was measured by the method described in 
Chapter 3, 
Production of 0 2 ' 
CM, MM and TM were stimulated with TP A, and the production of ROI, as 
indicated by the 02" level, was determined by the method described in Chapter 2. 
Radioimmunoassay 
Extraction of cellular thyroid hormones form cells 
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The levels of T3 and T4 in serum samples, macrophages and lymphocytes were 
measured according to the method described by Wong and his colleague (1980). For 
cellular thyroid hormone level, pellets of macrophages and lymphocytes were lysed 
in 0.1 ml 17 N NH4OH under vigorous agitation. Thyroid hormone was then 
extracted with 9.9 ml absolute alcohol for 5 min and centrifuged at 2000 rpm. This 
process of extraction was repeated once more using 5 ml NH4OH/absolute alcohol 
(1:99’ v/v). The supernatant was collected and dried under an air stream in a 37°C 
water bath, and the residues were redissolved in 0.08 M barbital buffer (16.494 g 
barbital sodium, 8 g BSA and 200 mg thlmerosal in 1 litre distilled water, titrated to 
pH 8.4 by HCL) for the determination of T3 and T4. 
Determination of T3 and T4 levels 
For the determination of T3 level in cell extract, 100 pi samples were mixed 
with 200 pi barbital buffer, 100 pi 2 % normal rabbit serum (NRS), 100 pi rabbit anti-
T3 BSA antibody (1:5000) and 100 pi 125I-T3 (Amersham, > 44 MBq/pg T3) in a 1.5 
ml microcentrifuge tube, and incubated at room temperature overnight. The test 
samples were precipitated in a cold room (4°C) for 1 h，and then reacted with 200 pi 
ice-cold secondary antibody (1:40, goat against rabbit, ABS Inc., California) in 10 % 
r " 
polyethylenglycol (PEG, Merck, 807491，USA). T3-antibody complex was equilibrated 
in the cold room for 30 min, and then centrifuged at 4°C with a speed of 9000 rpm 
for 5 min. The pellet was washed with 1 ml ice-cold barbital sodium buffer without 
BSA before they were subjected to measurement by a gamma counter. The amount 
of T3 was calculated from the standard curve constructed using known concentrations 
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of T3. For the measurement of T3 levels in serum samples, a similar procedure was 
performed，except that 100 pi 8-anilinonaphthalene-l-sulphuric acid (ANS, 120 mg/dl, 
Serva，13649, Germany) was added before the overnight precipitation step. 
Both cellular and serum T4 levels were measured using a modified method 
described above. As anti-T4 antibody (Corning, 02162, USA) was linked to glass 
bead, secondary antibody was not needed to precipitate the antibody-thyroid hormone 
complex. Besides, 125I-T4 (Amersham, > 44 MBq/pg T4) was used as tracer. 
Analysis of Data 
Results are expressed as means 土 standard deviation. Student's t test was used 
to compare the difference between various groups. Difference with a p < 0.05 were 
considered as statistically significant. 
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Results 
In vitro production of TNF 
The capability of macrophages to produce TNF in response to LPS is shown 
in Figure 5.1. The kinetics of in vitro TNF production by MM was similar to that of 
CM, with the exception that a lesser amount (p < 0.01) of TNF was found after 1 h 
of LPS stimulation. This decrease was normalised in TM, indicating that thyroid 
hormone can interfere with the early phase of TNF production by cultured 
macrophages. No significant difference in TNF production was observed among CM, 
MM, and TM after 2 h or 4 h of LPS administration. 
In vitro production of RNI 
The production of RNI by the 3 groups of macrophages (CM, MM, TM) in 
response to LPS, crude lymphokines alone, and LPS plus crude lymphokines is shown 
in Figure 5.2. It was found that MM, irrespective of the treatment used, showed a 
weaker ability to produce RNI in comparison to CM. The suppressive effect of MMI 
treatment on macrophages could be reversed by T4 replacement, that is, TM secreted 
an amount of RNI comparable to that secreted by CM. 
02" production 
The ability of all 3 groups of macrophages to produce superoxide radicals is 
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shown in Figure 5.3. One million control macrophage (CM) produced 6.8 yiM 02' 
while only 50 % of 02" (3.6 pM/million cells) was produced by MM, indicating that 
the MMI treatment diminished the in vitro production of 02". The suppressive effect 
of MMI seemed to be normalised, to some extent (4.9 pM/million cells), by T4 
replacement. 
Thyroid hormone level in serum samples and cell extracts 
The levels of T3 and T4 in serum samples and cell extracts were measured by 
radioiinmunoassay, and calculated from the standard curves constructed using known 
‘ concentrations of T3 and T4 (Figure 5.4 and 5.5), A significant decrease (p < 0.001) 
in the level of serum T4, but not T3, was observed after MMI treatment (Table 5.1). 
The level of serum T4 seemed to decline progressively with the duration of MMI 
treatment, but after T4 replacement it was restored to a level (45 nM) that was 
comparable to the level in normal mice. Surprisingly, T4 replacement appeared to 
cause a slight decrease in serum T3 level (Table 5.1). 
The effect of in vivo MMI treatment on the cellular levels of thyroid hormones 
was also studied in this experiment. Table 5.2 shows that the T4 levels (167 
pM/inillion cells' and 46 pM/niillion cells respectively) in macrophages and 
splenocytes decreased with the duration of MMI treatment, and became undetectable 
after 6 weeks of MMI treatment. The T3 levels (19.4 pM/million cells) in 
macrophages decreased with the duration of MMI treatment, but the T3 level remained 
at normal value (8-10 pM) in lymphocytes after 6 weeks of MMI treatment. 
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Figure 5.1 Production of tumor necrosis factor (TNF) by peritoneal macrophages 
isolated from control (CM), MMI-treated (MM) mice and MMI-treated 
mice with T4 replacement (TM). The cells were then challenged with 
lipopolysaccharide (LPS) in vitro for 1，2 and 4 h. The results are 




^ 40 - 2 ^ 
CTL LPS CLK LPS + CLK 
Trea tment 
Figure 5.2 Production of reactive nitrogen intermediate (RNI) by peritoneal 
macrophages isolated from control (CM), MMI-treated (MM) mice and 
MMI-treated mice with T4 replacement (TM). The cells were stimulated 
in vitro v/ith lipopolysaccharide (LPS), crude lymphokines (LK) and a 
combination of LPS + LK. The results are expressed as means 土 
standard deviation (n=6). **p < 0 . 0 1 ， < 0 . 0 0 1 . 
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Figure 5.3 Production of reactive oxygen intermediates (ROI) by peritoneal 
macrophages isolated from control (CM), MMI-treated (MM) mice and 
MMI-treated mice with T4 replacement (TM). The cells were 
stimulated in vitro with phorbol 12-myristate 13-acetate 4-o-methylester 
(TPA) for 1 h‘ The results are expressed as means 土 standard 
deviation (n=6). *p < 0.05, < 0.001. 
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Figure 5.4 The triiodothyronine (T3) standard curve constructed using known 
concentrations of T3. The results are expressed as means 土 standard 
deviation (n=6). 
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Figure 5.5 The thyroxine (T4) standard curve constructed using known 
concentrations of T4. The results are expressed as means 土 standard 
deviation (n=6). 
88 
Duration of MMI treatment (wks) Serum T3 (nM) Serum T4 (nM) 
0 - 1 . 5 7 土 0 . 1 3 5 9 . 7 7 土 8 . 4 0 
2 1 . 5 8 土 0 . 1 4 5 7 . 9 8 土 4 . 6 0 
4 1 . 5 5 土 0 . 2 3 2 2 . 8 4 士 2 , 0 8 * * * 
6 1.41 ± 0 . 0 7 15 .80 ± 1 . 8 9 * * * 
6 plus T4 replacement 0.94 土 0.20 44.96 土 12.67 
Table 5.1 The serum levels of triiodothyronine (T3) and thyroxine (T4) in 
methimazole-treated mice and in methimazole-treated mice receiving 
thyroxine (T4) replacement (2.8 pg/mice). The results are expressed as 
means 土 standard deviation (n=10). < 0.001 
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T3 (pM/106 cells) T4 (pM/106 cells) 
MMI treatment (wks) M(|) LM M(|) LM 
0 1 9 . 4 ± 3 . 4 1 0 . 1 土 1 . 9 6 1 6 7 . 5 土 4 . 6 6 4 6 . 3 ± 0 . 9 2 
2
 1 5 . 2 士 1 . 7 5 7 . 9 5 土 1 . 3 3 8 7 . 3 0 土 5 . 9 * * * 3 1 . 9 ± 1 . 4 6 * * * 
4 9.75 土 1.43** 9.92 ± 1.58 43.90 土 4 . 9 林 * 29.0 土 5 . 7 * * * 
6 1 1 . 0 士 1 . 4 5 * * 8 . 2 3 土 1 . 9 3 U D U D 
Table 5.2 The cellular thyroid hormone levels in mice after methimazole 
treatment. The results are expressed as means 土 standard deviation 
(n=5). M(|): macrophages, LM : lymphocytes, UD : undetectable. **p 
< 0 . 0 1 ， < 0.001. 
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Discussion 
MMI is an antithyroid drug that modifies thyroid function by inhibiting thyroid 
hormone synthesis and release. The decrease in serum T4 concentration may trigger 
the release of TSH from the pituitary with consequent goitre. The level of serum T3， 
however, remains constant for at least 1-2 months after MMI treatment, until the 
intrathyroidal hormone store has been depleted (Larsen & Silva，1983). This probably 
reflects a compensatory mechanism so as to utilize smaller amounts of iodine to 
produce a metabolically more potent thyroid honnone (Evered, 1975). Therefore 
serum T3 level has little value in the confirmation of hypothyroidism because it is 
frequently normal, even when the patient is clinically hypothyroid, and both serum T3 
and T4 levels decrease to subnormal levels only in more severe hypothyroidism 
(Hamburger，1991). In this experiment, the mice had their serum T4 level decreased 
by more than 3 fold while no change in serum T3 was observed after MMI treatment 
(Table 5.1). This implies that, according to the serum thyroid hormone (T4) level, 
mice after 6 weeks of MMI treatment suffered from hypothyroidism. 
The circulating thyroid hormones enter the cell in the free unbound form either 
by passive diffusion or by an energy-dependent transport system that has not been 
clearly defined (Larsen et al” 1981; Kvetny & Matzen，1990). After entry into the 
cells, thyroid honnone interacts with a nuclear receptor directly without prior 
association with a cytoplasmic receptor, as in the case of steroid hormones. Both T3 
and T4 have their specific binding sites in cells, although T3 binds to this receptor with 
a much higher affinity than does T4 (Andreoli, 1981). The thyroid hormone-receptor 
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complex is presumably involved in transcriptional and/or post-transcriptional nuclear 
events that result in an increase in accumulation of specific mRNA molecules coding 
the synthesis of specific proteins regulated by thyroid hormones (Oppenheimer, 1985; 
Weinstein et al.’ 1991), Recent evidence suggests that the proto-oncogene c-erb-A, 
a cellular counterpart of the v-erb-A oncogene of avian erythroblastosis virus, encodes 
a receptor for thyroid hormone, and the hormone-receptors are transcriptional 
enhancers (Sap et al” 1986; Weinberger et al., 1986). In this experiment, the cellular 
level of T4 decreased with the duration of MMI treatment, falling below the detectable 
level after 6 week (Table 5.2). This is well correlated with the decrease of serum T4 
level after MMI treatment (Table 5.1)，and thus a lesser amount of T4 is available for 
diffusion into the cells. However, there was no change in T3 level in lymphocytes 
whereas a mild significant decrease was observed in the ease of macrophages (Table 
5.2)，while the serum 丁3 was maintained at a constant level (Table 5.1). The relatively 
constant level of T3 may be explained by the striking increase in T4 to T3 conversion 
in cells during hypothyroidism (Larsen & Silva, 1983), as in the case of serum thyroid 
hormone level, ‘ 
One way to relief hypothyroid symptoms is to administer the patients with 
thyroid hormone. Thyroxine is chosen for the replacement therapy because of its slow 
turnover rate, so that the thyroid hormone need not be administered more than once 
a day (Waldstein, 1990). It was reported that T4 administered subcutaneously was 
absorbed rapidly, reaching maximal levels in 2 to 4 h (Sekadde et al” 1974) and its 
turnover rate was only about 10 % per day whereas was turned over much more 
rapidly, about 75 % per day (Utiger, 1987). Therefore, T4 was used in the 
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replacement therapy to maintain a more steady thyroid hormone level in the MMI-
treated mice in this experiment. It was found that hypothyroid mice given % for 6 
consecutive days had a normal serum T4 level as well as immune responses. 
Larsen and Silva (1983) suggested that most of the body tissues remained 
euthyroid and no thyroid hormone replacement was anticipated if plasma T3 was 
normal (Larsen & Silva, 1983). Indeed, it was emphasized by some researchers that 
T3 was the only active thyroid hormone and the action of T4 was mediated by its 
conversion to T3 (Oppenheimer, 1983). On the other hand, the presence of lower 
binding affinity (20 % of that of T3) of T4 to thyroid binding domain and the 
recognition between serum T4 concentrations and clinical data of physiological status 
suggested that T4 molecule has intrinsic biological activity without prior conversion 
to the more potent T3 molecule (Andreoli, 1981; Halperin et al., 1991). In previous 
studies, macrophages in hypothyroid mice showed a diminished ability to produce 
TNF, RNI and 0 2 ' (Chapter 2)，and the lymphocytes had lowered mitogenic responses 
(Chapter 3). The suppressive effects of hypothyroidism seemed to correlate with the 
serum and cellular levels of T4, and to a lesser extent, the T3 level (Table 5.1 and 5.2). 
As shown in this chapter, the immunosuppressive action of MMI on macrophages 
could be normalised when serum T4 level returned to normal by T4 replacement, and 
preliminary data suggested that the decreased proliferative responses of splenocytes 
from MMI-treated mice can also be reversed by T4 replacement (unpublished data). 
From the results of the present study，we can therefore conclude that there was a 
reduction in the functions of macrophages and lymphocytes in MMI-induced 
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Chapter 6 General Discussion 
Graves, disease is the commonest cause of hyperthyroidism and may occur at 
any age, more commonly in females than in males. The cause of the disease is still 
unknown, but it may be due to infiltration of T lymphocytes into the thyroid gland, 
which stimulates B lymphocytes to synthesize autoantibodies, such as thyroid 
stimulating immunoglobulin (TSI), to act against these antigens (Weetman & 
McGregor，1984; Burman & Baker，1985, McGregor, 1990). Volpe (1978) has 
suggested that the generation of TSI is due to a defect in immunoregulation with a 
failure of suppressor T cell function and thus allowing helper T cells to stimulate B 
lymphocytes to produce immunoglobulins directed against the thyroid gland. 
Methimazole (MMI) is widely used in the treatment of Graves' disease, because it 
inhibits the synthesis of thyroid hormones and the production of autoantibodies 
(DeGroot, 1979; Hallengren et 1980; Bagnasco et al., 1990). 
Two major theories have been proposed to explain the immunomodulatory , | 
effect of MMI (Mechanick & Davies，1990). The first theory asserts that there is a 
direct action of MMI on the immune system, because MMI is concentrated in 
macrophages, monocytes and other antigen presenting cells, and thus interferes with 
H202 generation of the cells (Weetman et al.’ 1984). Significant decreases of thyroid 
stimulating immunoglobulin and lymphocyte infiltration into the thyroid gland and 
thymus, as well as killer (K) cell and natural killer (NK) cell populations were 
observed in patients with Graves' disease receiving MMI treatment (Pozzilli et al., 
1982; Ferguson et al” 1984; Okabe et al., 1984). However, in vitro treatment with 
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MMI did not affect K or NK cell function (Weetman et al” 1985), PHA-induced T 
cell proliferation (Bagnasco et al., 1990) as well as IL-1, IL-2 and IFN production 
(Weetman, 1986; Bagnasco et al., 1990). 
The second theory proposed that all the derangements in the immune system 
is due to a thyroid hormone deficiency caused by MMI (Volpe al” 1986, 1987). 
According to this model, MMI suppressed the over-production of thyroid hormones 
in patients with Graves* disease. It is also known that thyroid hormone therapy can 
normalise the immunosuppressive effect in MMI-induced hypothyroid rats (Starling 
& Weese，1985). This study was, therefore, undertaken to study the 
immunomodulatory effect of MMI, both in vivo and in vitro, on the functions of 
macrophages and lymphocytes in inbred mice. In addition, we tried to correlate the 
cell functions with the levels of thyroid hormones‘ ^ 
This study demonstrates that in vivo treatment of MMI decreased the 
macrophage functions by lowering TNF gene expression at both transcriptional and 
translational levels, and the in vitro production of RNI and ROI from the cells upon 1 
stimulation (Chapter 2), which may underlie bactericidal and tumoricidal activities of 
MMI-treated mice and rats (Starling & Weese，1985; Liu et al” 1989, 1991). The 
proliferative responses of T and B lymphocytes to Con A and LPS were weakened, 
and this may be due to the decline in IL-2 production from lymphocytes after MMI 
treatment, which is essential for proliferation of lymphocytes (Dinarell et al., 1987). 
The IL-2 released from lymphocytes also stimulated itself to produce IFNy (Kronke 
et al” 1985)，and thus the IFNy production in the crude lymphokines was also reduced 
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in MMI-treated mice. IFNy exerts an inductive effect in the production of TNF by 
priming the macrophages prior to LPS stimulation (Arai et al” 1990; Davila et al., 
1990). In this study, the changes in the crude lymphokine content also hindered the 
lymphocyte-macrophage interaction by reducing the production of TNF and RNI from 
macrophages (Chapter 3). All these findings suggest that cellular MMI accumulation 
is not the major reason for the immunosuppressive effect of in vivo MMI treatment. 
Even when exposed to 1-1000 yiM MMI in the culture, which is unlikely to be 
achieved in the peripheral tissue in vivoy macrophages showed no changes in the 
production of TNF, RNI and ROI while the proliferative responses of lymphocytes 
also remained unchanged. This finding coincided with the results obtained in other 
laboratories (Weetman et al., 1985; Bagnasco et aL, 1990), and also ruled out the 
possibility that the immunomodulatory effects of MMI were due to its direct cytotoxic 
effects on the macrophages and lymphocytes. 
According to the present results, the serum and cellular levels of T4 decreased 
significantly after MMI treatment and the immunomodulatory effects of MMI were 
likely to be mediated by its antithyroid activity (Chapter 5). These circulating thyroid 
hormones enter the cells by passive diffusion or by facilitated transport, and 
modulating responsive gene function by binding to the specific nuclear receptor 
(Larsen et al., 1981; Kvetny & Matzen’ 1990). The functional assays of lymphocytes 
and macrophages correlate very well with the T4 levels. Although T3 binds to its 
nuclear receptor with a higher affinity, T4 also accounts for 5.4-10 % of the occupied 
nuclear receptors (Andreoli, 1981; Halperin et al., 1991), suggesting a potential role 
of T4 in biological activity. Abundant evidence suggests that thyroid hormones 
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• regulate gene expression through binding to the nuclear receptor, which further 
interacts with the thyroid responsive element of the responsive gene (Oppenhemier, 
1985; Weinstein et al” 1991). More recent findings suggested that the product of the 
proto-oncogene, c-erbA, is a thyroid hormone receptor which is a transcriptional 
enhancer (Sap et al” 1986; Weinberger et al,, 1986). Moreover, the 
immunosuppressive actions of MMI on macrophages and lymphocytes could be 
reversed by T4 replacement therapy. The functions of macrophages and lymphocytes 
in MMI-treated mice returned to normal after subcutaneous injection of T4 for 6 
consecutive days. These results indicate that MMI exerts its immunological effects 
by lowering the thyroid hormone synthesis from the thyroid gland and finally this 
results in reduction of serum and cellular T4 levels which may directly hinder the 
functions of macrophages and lymphocytes. This is supported by the findings which 
show that the immunomodulatory effects of MMI are mediated by its antithyroid 
effect (Volpe et al, 1986, 1987) and hypothyroid status in the body may result in 
diminished immune response (Starling & Weese, 1985; Liu et al., 1991). 
Although this report demonstrated that the immunomodulatory effects of MMI 
on inbred mice were mainly attributed to a decrease in T4 production, the level of T3 
remained at a constant level. This observation differs from the results obtained from 
rats. In our laboratory, we found that rats showed a drastic decrease in body weight 
and serum T3 level after 6 weeks of MMI treatment. This was not found in MMI-
treated mice (unpublished data). Moreover, the production of TNF by mouse 
peritoneal macrophages was found to vary form strain to strain (Jacob, 1992). 
Therefore, further investigations should be performed to see whether similar results 
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can be obtained from another species of animal. 
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